Infantile Batten Disease: Effective Therapy and Novel Model by Shyng, Charles
Washington University in St. Louis
Washington University Open Scholarship
Arts & Sciences Electronic Theses and Dissertations Arts & Sciences
Summer 8-15-2016
Infantile Batten Disease: Effective Therapy and
Novel Model
Charles Shyng
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted
for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For
more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Shyng, Charles, "Infantile Batten Disease: Effective Therapy and Novel Model" (2016). Arts & Sciences Electronic Theses and
Dissertations. 896.
https://openscholarship.wustl.edu/art_sci_etds/896
 WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Molecular Cell Biology 
 
Dissertation Examination Committee: 
Mark S Sands, Chair  
John Cirrito 
David H. Gutmann 
Jin-Moo Lee  
Steven J. Mennerick 











A dissertation presented to the  
Graduate School of Arts & Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 






















Table of Contents 
List of Figures ................................................................................................................................ iv 
List of Abbreviations ...................................................................................................................... v 
Acknowledgements ........................................................................................................................ vi 
Abstract of the Dissertation ........................................................................................................... ix 
Chapter 1: Introduction ................................................................................................................... 1 
Lysosomal Storage Diseases ..................................................................................................................... 2 
Neuronal Ceroid Lipofuscinoses ............................................................................................................... 3 
Infantile Neuronal Ceroid Lipofuscinosis .................................................................................................. 4 
The murine INCL model ............................................................................................................................ 6 
INCL Therapy ............................................................................................................................................. 8 
Small molecule drugs ............................................................................................................................ 8 
Cross-correction .................................................................................................................................... 9 
Cell-mediated Therapy ........................................................................................................................ 10 
Goals of the Thesis .................................................................................................................................. 12 
Spinal Cord pathology ......................................................................................................................... 12 
Multiple cell types involved in INCL pathogenesis.............................................................................. 13 
Tethered PPT1 to the lysosomal membrane ...................................................................................... 15 
Chapter 2: A new and effective therapeutic target for Infantile Batten disease ........................... 17 
Introduction ............................................................................................................................................ 18 
Material and Methods ............................................................................................................................ 21 
Results ..................................................................................................................................................... 27 
Intracranial AAV2/9-hPPT1 is superior to AAV2/5-hPPT1. ................................................................. 27 
Spinal Cord disease in IC-treated PPT1-/- animals .............................................................................. 28 
Spinal Cord Pathology in INCL ............................................................................................................. 29 
Summary of Brain and Spinal Cord INCL Pathogenesis ....................................................................... 34 
Differential PPT1 activity in the brain and spinal cord following intracranial and intrathecal AAV2/9-
hPPT1 .................................................................................................................................................. 35 
Intracranial and Intrathecal AAV2/9-hPPT1 reduce histological markers of INCL .............................. 38 
IC-AAV2/9 and IC/IT-AAV2/9 decrease cortical atrophy ..................................................................... 39 
Combination therapy reduces neuroinflammation in brain and spinal cord ..................................... 41 




Chapter 3: Cell-limited expression of PPT1 ................................................................................. 53 
Introduction ............................................................................................................................................ 54 
Materials and Methods ........................................................................................................................... 56 
Results ..................................................................................................................................................... 61 
Lysosomal Membrane-Tethered PPT1 ................................................................................................ 61 
PPT1-LAMP1 function in vitro ............................................................................................................. 62 
Generation of a PPT1-LAMP1 transgenic animal ................................................................................ 64 
Founder #42 analyses ......................................................................................................................... 66 
PPT1-LAMP1 expression in vivo is ubiquitous and prevents AFSM .................................................... 68 
PPT1-LAMP1 ubiquitous expression in vivo prevents behavioral decline and extends longevity ...... 70 
Discussion................................................................................................................................................ 71 
Chapter 4: Summary, Conclusions, and Future Directions........................................................... 75 
Summary and Conclusions ...................................................................................................................... 76 
A new target and effective therapy for INCL ...................................................................................... 76 
Conclusion from combination therapy ............................................................................................... 79 
Future Directions for INCL gene therapy ............................................................................................ 81 
Summary of cell-limited study of PPT1 ............................................................................................... 86 
Conclusions from cell-specific expression of PPT1 ............................................................................. 87 
Future Directions for Cell-specific Study of INCL ................................................................................ 88 
References ..................................................................................................................................... 91 
Curriculum Vitae ........................................................................................................................ 108 











List of Figures 
 
Figure 1. AAV2/9 is superior to AAV2/5 but does not correct the spinal cord 
Figure 2. Progressive accumulation of autofluorescent storage material 
Figure 3. Regional Volume measurements of PPT1-/- spinal cords 
Figure 4. Progressive astrocytosis in the spinal cord 
Figure 5. Progressive microgliosis in the spinal cord 
Figure 6. Diagram of temporal pattern of INCL brain and spinal cord pathology 
Figure 7. PPT1 and Secondary enzyme activity in treated animals 
Figure 8. Histochemical stain for PPT1 activity 
Figure 9. Autofluorescent storage material is reduced in the combination treated animals 
Figure 10. Cortical atrophy and brain mass is normalized in the combination therapy 
Figure 11. Microgliosis is reduced in the combination treated animals   
Figure 12. Astrocytosis is reduced in the combination treated animals 
Figure 13. Cytokine analysis of treated animals at 7 months 
Figure 14. Functional and behavioral phenotype is improved with the combination therapy 
Figure 15. Mockup and Sequence of PPT1-LAMP1 
Figure 16. In vitro characterization of PPT1-LAMP1 
Figure 17. Generation of a cell-specific transgene 
Figure 18. Generation of transgenic animals and identification of loxP site recombination 
Figure 19. In vitro characterization of F42 
Figure 20. Biochemistry and Histology in F42 




List of Abbreviations 
 
AAV       Adeno-associated virus 
AFSM       Autofluorescent storage material 
ANOVA      Analysis of Variance 
CNS       Central Nervous System 
ERG       Electroretinography 
ERT       Enzyme replacement therapy 
GFAP       Glial Fibrillary Acidic Protein 
GROD       Granular Osmophilic Deposits  
IC       Intracranial 
IC/IT       Intracranial/Intrathecal 
INCL       Infantile Neuronal Ceroid Lipofuscinosis 
IT       Intrathecal 
LAMP1      Lysosome-associated membrane protein-1 
LSD       Lysosomal storage disease 
NCL       Neuronal Ceroid Lipofuscinoses 
PBS       Phosphate-buffered Saline 
PFA       Paraformaldehyde 
PPT1       Palmitoyl-protein thioesterase-1 
PPT1-/-      PPT1-deficient 
S1BF       Somatosensory barrel field cortex 
TBS       Tris-buffered saline 
VPM/VPL      Ventral posterior thalamic nucleus 







 I could not be at this point in my life without the sacrifice and generosity of my parents, 
my family, my thesis advisor, my friends, my beloved fiancé, and my thesis lab members. I am 
sincerely thankful for their encouragement and love.  
 I would like to thank my mom and dad. Without their constant and unwavering support, 
love, and encouragement, I would not be where I am today. Their sacrifice so that I could be who 
I am today and who I will become tomorrow is not one that can be repaid. I thank them for 
instilling in me perseverance and dedication. I thank them for teaching me to see the light and to 
find joy when nothing seems to go right. I thank them for teaching me that one never stops 
growing. From a young age, they encouraged me to open my mind and explore the world, to 
absorb as much knowledge as I could, and to use my talent and skills to help others. I take that 
with me every day.  
 I would like to thank my thesis advisor, Dr. Mark Sands. Mark took me into his lab as a 
goofy kid who knew little and has molded me into a well-rounded scientist. He gave me the 
opportunity to apply myself and to succeed in graduate school. Mark provided constant guidance 
through his open door policy. His willingness to answer my constant questions, listen to my 
crazy ideas, help with writing grants and papers, and allowing me to observe daily PI life helped 
me to grow scientifically. Mark taught me so much about science and about people. From him, I 
learned how to conduct sound basic and translational science. I learned why we perform these 
studies. His dedication to helping patients and families is inspirational. His effort to instill that in 
his graduate students is commendable. Through scientific and patient conferences, I was able to 
see first-hand the impact our work would have on patients and their families. I cannot thank him 
enough for these eye-opening opportunities. I thank Mark for believing in and supporting me, for 
vii 
 
giving me the opportunity to find my own interests, and for being such an amazing role model 
for a goofy kid. 
 I would like to thank my thesis lab for their laughter and insights. I have learned a great 
deal about science and about life from my interactions with current and former lab mates. I 
would like to thank Marie for being the awesome ‘lab mom’ and dealing with all the messes and 
general craziness. I would like to thank her for helping me get on my feet when I first joined the 
lab. Marie has always being there when I had questions or if I just needed someone to talk to. I 
would like to thank Kevin for always bringing laughter to my bay. I thank him for working so 
diligently, and for teaching me how to run a mouse colony and how to cryosection. I thank 
Bruno for being such a great friend both in and out of the lab. I thank him for all the guidance he 
has provided with experiments and for being so willing to pass on knowledge. 
 I would like to thank my closest friends for their constant support and their ability to keep 
me grounded. I have had the opportunity to make friends inside and outside of graduate school. 
To my friends within the graduate school, I thank you for all the scientific conversations we’ve 
had throughout the years and for all the fun times we’ve had outside of lab such as our monthly 
food club. I could not imagine going through graduate school without such wonderful friends to 
share the experience with. To my friends outside of graduate school, I thank you for all the joys 
and laughter. I have watched our circle of friends grow with new additions, with two more tiny 
ones on the way. Thank you for keeping me grounded, for continuing to support me through all 
of my highs and lows, and for dealing with my peculiarities. 
 I want to thank my beloved fiancé Brea Jewell. I never imagined that I would meet the 
love of my life right down the hall. Thank you for always believing in me and for always 
grounding me. Thank you for always being a source of joy and laughter. You have shown me 
viii 
 
that there is more to life than just lab and soccer. Thank you for all the countless things you do 
for me daily. Most of all, thank you for always being there for me. I look forward to our many 
years ahead.  
 Lastly, I want to thank all the mentors I have had and my thesis committee. I would not 
be here today without the scientific mentorship from these individuals. I want to thank my uncle, 
Dr. Yao-wen Huang, for giving me my first foray into the lab. Thank you for teaching me about 
the scientific method and allowing me to conduct my first scientific experiment. Thank you for 
supporting me throughout this entire PhD process. I want to thank the Young Scholars Program 
at the University of Georgia for giving me the opportunity to continue my scientific curiosities 
while in high school. I thank Drs. Steven Stice and Amy Batal for providing an encouraging 
environment for a young scientist to grow. I want to thank Dr. James Huettner for the 
opportunity to work in his lab while in college. Thank you for allowing me to pursue my 
interests and teaching me along the way. The experience I gained in your lab has been 
instrumental while in graduate school. I want to thank Dr. Jonathan Cooper and Hemanth 
Nelvagal for their collaboration, hard work, and help with our mutual work. Finally, I want to 




Abstract of the Dissertation 
 
Infantile Batten Disease: Effective Therapy and Novel Model 
by 
Charles Shyng 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2016 
Mark S. Sands, Chairperson 
 
Infantile neuronal ceroid lipofuscinosis (INCL, Infantile Batten) is typically an early 
onset, neurodegenerative lysosomal storage disorder. INCL is caused by mutations to the gene 
CLN1 which codes for the lysosomal enzyme palmitoyl-protein thioesterase-1 (PPT1). PPT1 is a 
soluble lysosomal enzyme that functions to cleave fatty acyl chains from proteins destined for 
degradation. Deficiency in PPT1 leads to the accumulation of autofluorescent storage material, a 
hallmark of the NCLs. The storage material has been implicated in progressive histopathological 
changes in the brain such as neuronal loss, astrocytosis, microgliosis, and immune cell 
infiltration. These histopathological changes result in a progression of clinical signs including 
vision loss, decline in motor function, cognitive deficits, seizures, and premature death. 
Currently, there are no cures or treatments for INCL. However, a murine model of INCL has 
been used in pre-clinical therapy studies. The PPT1-/- mouse has been shown to be a reliable 
model for the human INCL disease. Detailed temporal and spatial histopathological 
examinations of murine INCL in the brain have led to intracranial gene therapy studies. These 
pre-clinical studies have resulted in significant improvements in biochemical, histopathological, 
and functional deficits seen in the untreated PPT1-/- mouse. However, there have only been 
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modest improvements in lifespan. Given the identification and development of improved gene 
therapy vectors, this was a surprising finding. Therefore, the first section of the dissertation, we 
pursued a more thorough characterization of the central nervous system to identify potential 
regions of disease not targeted by intracranial gene therapy. We identified the spinal cord as a 
significant site of disease that was not previously characterized or corrected. This allowed us to 
target both the brain and spinal cord with AAV-based gene therapy. We demonstrated that 
targeting the entirety of the central nervous system was necessary to treat INCL more effectively. 
From these and historical studies, we identified a multitude of cell types that are involved 
with INCL pathogenesis. In the central nervous system, INCL has been shown to progress 
sequentially from astrocytosis, to neuronal loss, to microgliosis and immune cell infiltration. 
PPT1 is ubiquitously expressed; therefore, its deficiency in INCL could lead to pathology in 
every cell type. Currently, we are unable to model cellular and metabolic changes in specific cell 
types in INCL due to ‘cross-correction’. While ‘cross-correction’ is beneficial for the 
development of therapeutics, it interferes with our ability to understand the role of PPT1 in 
specific cell types. Therefore, in the second section of the dissertation, we sought to determine 
the cell-autonomous nature of PPT1. Because PPT1 is a soluble lysosomal hydrolase that can 
undergo ‘cross-correction’, we developed a chimeric enzyme whereby PPT1 is tethered to the 
lysosomal membrane. We demonstrated that tethered PPT1 retains its enzymatic function and 
does not ‘cross-correct’ in vitro and in vivo. We further demonstrated that near-ubiquitous 
expression of tethered PPT1 could prevent INCL. This lays the groundwork for future studies 




























Lysosomal Storage Diseases 
 
Lysosomal storage diseases (LSDs) are a group of rare, inherited metabolic disorders that 
include over 45 different diseases (Boustany, 2013; Cox & Cachon-Gonzalez, 2012; Hers, 1965; 
Neufeld, 1991; Schultz et al, 2011). LSDs occur with an incidence of approximately one in 8000 
live births, making them one of the most common childhood genetic diseases (Fuller et al, 2006; 
Schultz et al, 2011). Each LSD is due to mutations to a single gene and occurs mostly with an 
autosomal recessive inheritance pattern (Neufeld, 1991). These mutations lead to deficiency or 
reduction in function of proteins involved in the lysosomal pathway. Functional loss or reduction 
of a lysosomal protein ultimately results in the accumulation of storage material either in the 
lysosome or extra-lysosomal. These deficiencies have been shown to cause an increase in 
lysosome proliferation and secondary effects on cellular metabolism (Vitner et al, 2010). The 
storage materials have been implicated in the pathogenesis of the clinical disease; however, 
precise studies to determine their role in pathology have not been performed. 
Lysosomal enzymes are ubiquitously expressed and their deficiency affects multiple cell 
types and organ systems. Their deficiency leads to a complex clinical presentation. Many LSDs 
present with clinical signs of organomegally, skeletal deformities, cardiac abnormalities, and/or 
immunologic deficiencies (Madhavarao et al, 2009). Interestingly, approximately two-thirds of 
all LSDs present with a neurological phenotype (Jardim et al, 2010). Those disorders that present 
with neurological dysfunction exhibit behavioral problems, regression in cognition, loss of visual 
acuity and hearing, verbal deterioration, and/or loss of motor function. Patients are typically 
diagnosed after disease onset which can range from early infancy to adulthood (Platt & 
Lachmann, 2009). Interestingly, the mutated gene does not necessarily determine the age of 
onset (Maire, 2001). It has been shown that these mutations lead to a variable scale of lysosomal 
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enzyme activity, which ultimately influences the progression of the disease. This most likely is 
caused by the presence of yet unknown modifying genes. Ultimately, patients suffer an early 
death after an undefined period of cognitive or behavioral regression. Currently, there are no 
comprehensive treatments for lysosomal storage disorders. However, there has been progress 
towards the development of effective therapies involving gene and cell therapy as well as the 
development of small molecule drugs and recombinant enzyme (Parenti et al, 2015). 
 
Neuronal Ceroid Lipofuscinoses 
 
The Neuronal Ceroid Lipofuscinoses (Batten Disease, NCL) are a group of mostly 
pediatric neurodegenerative diseases (Goebel & Wisniewski, 2004). The incidence of Batten 
disease is ~1 in 12,500 live births making it the most common inherited pediatric neurologic 
disorder. This subgroup of lysosomal storage disorders are grouped together due to their 
common histologic hallmark of autofluorescent storage material (AFSM) accumulation (Mole & 
Williams, 1993). There is a variety of forms of Batten disease which have been historically 
classified based on age of onset (Dyken, 1989). However, in recent years, it has been determined 
that age of onset and the mutated gene are not necessarily correlated (Wisniewski et al, 2001). 
Presently, the various forms of Batten disease are classified based on the mutated gene. Currently 
there are over 14 different genes associated with NCL (Anderson et al, 2013). The progression of 
histopathogenesis in the brain has been well documented among the NCL variants (Bennett & 
Rakheja, 2013). The similarities in disease progression include neuronal loss, retinal 
deterioration, cortical thinning, brain atrophy, and neuroinflammation. The accumulation of 
AFSM is present in all variants, though the identification of AFSM substrates and whether 
AFSM is pathogenic has not been elucidated (Palmer et al, 2013). It has also been recently 
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shown in patients and murine models that NCL variants have metabolic and cardiac 
abnormalities (Galvin et al, 2008; Ostergaard et al, 2011; Woloszynek et al, 2007). Since the 
NCL field had largely focused on disease associated with the brain, these recent discoveries have 
led to studies focusing on systemic disease. Most studies have been directed to study the brain, 
while the spinal cord (central nervous system), the peripheral nervous system (PNS), and the 
autonomic nervous system (ANS) have been largely overlooked.  
 
Infantile Neuronal Ceroid Lipofuscinosis 
 
The infantile form of NCL is one of the earliest onset and most aggressive forms of 
Batten disease. Infantile NCL (INCL) was first described in 1973 by Haltia et al and 
subsequently referred to as Santavuori-Haltia disease (Haltia et al, 1973b; Santavuori et al, 
1973). While most cases of INCL were located in the Scandinavian region, with the 
improvement in genomic techniques, INCL has been described worldwide with ages ranging 
from infancy to adulthood (Hofmann et al, 2001b; Kousi et al, 2012). Children with INCL are 
pre-symptomatic at birth but begin exhibiting psychomotor retardation between 6-12 months. 
Developmental regression begins first with loss of motor and visual functions followed by 
cognitive decline. As the disease progresses, patients become blind and ataxic, eventually losing 
complete muscle coordination and tone. Patients also develop myoclonic seizures. Near end of 
life, patients are wheelchair bound and are often on feeding tubes and ventilation (Jadav et al, 
2014; Santavuori et al, 1974; Santavuori et al, 1973; Simonati et al, 2009). Currently, there are 
no effective treatments for INCL. 
Mutations leading to INCL were identified in the CLN1 gene in 1991 (Schonherr et al, 
1991). Since then, over 61 novel mutations have been identified in the CLN1 gene (Kousi et al, 
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2012). They consist of missense, nonsense, splicing affected, insertions, deletions, or a 
combination of mutations. These mutations lead to reduced enzymatic activity of PPT1. The 
enzymatic deficiency leading to INCL was not discovered until 1995 (Vesa et al, 1995). The 
authors showed that palmitoyl-protein thioesterase-1 (PPT1), a soluble lysosomal hydrolase, was 
deficient in INCL patients. A follow-up study showed that replacement of PPT1 via recombinant 
enzyme was able to correct the disease in in vitro lymphoblast cultures (Camp & Hofmann, 
1993; Camp et al, 1994; Hellsten et al, 1996; Hofmann et al, 2001a; Verkruyse & Hofmann, 
1996; Verkruyse et al, 1997). PPT1 functions to cleave fatty acyl groups from modified cysteine 
residues in proteins destined for degradation. It is ubiquitously expressed and has been shown to 
be developmentally and spatially regulated (Isosomppi et al, 1999). Recently, PPT1 has been 
shown to co-localize with synaptic vesicles and synaptosomes in neurons, however, the reason 
has yet to be discovered (Kim et al, 2008; Lehtovirta et al, 2001). Deficiency in PPT1 leads to 
the biochemical, histological, and behavioral changes associated with INCL. 
The cellular pathology in PPT1 deficiency has the hallmark of NCLs, autofluorescent 
storage material. The ultrastructural appearance of storage material has been described as 
granular osmiophilic deposits (GRODs) (Goebel et al, 1995; Siegismund et al, 1982). These 
deposits are localized to the lysosome and their complete composition has yet to be determined. 
However, it has been shown in the brain to contain a complex mixture of protein and lipids with 
major products of saposin A and D and glial fibrillary acidic protein (GFAP) (Tyynela et al, 
1993).   
Analyses of the INCL brain show gross anatomical changes. There is severe brain 
atrophy such that the mass of the INCL brain is only 50% of an age-matched normal child 
(Haltia et al, 1973a). There is dramatic thinning of the cortical layers. The accumulation of 
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lipopigments has been found ubiquitously, however, the extent of their accumulation varies. 
They are prevalent in the brain, reticuloendothelial system, intestine, bone marrow, and Kupffer 
cells (Siegismund et al, 1982). Using magnetic resonance imaging, atrophy was seen in the 
thalamus and basal ganglia by T2 hypointensity as well as in the cerebral cortex (Jadav et al, 
2014; Jadav et al, 2012; Santavuori et al, 1992; Vanhanen et al, 1995a). This was correlated with 
loss of cortical neurons as well as loss of axons and myelin sheaths (Vanhanen et al, 1995a; 
Vanhanen et al, 1995b). There is also atrophy of the retinal pigment epithelial cells and 
accumulation of GRODs ultimately leading to loss of an electroretinography (ERG) signal 
(Vanhanen et al, 1997; Weleber et al, 2004) 
 
The murine INCL model 
 
A mouse model of INCL was created in 2001 that is deficient in PPT1 activity (PPT1-/-) 
(Gupta et al, 2001). This model had a neomycin cassette inserted into exon 9 of the murine PPT1 
gene via homologous recombination. This mutation introduced a premature stop codon as well as 
abolished two of the amino acids involved in the catalytic triad. Characterization of the mouse 
model has been extensive with much of the studies focused on the brain (Dearborn et al, 2015; 
Galvin et al, 2008; Gupta et al, 2001; Kielar et al, 2007; Macauley et al, 2009). The PPT1-/- 
mouse has a median lifespan of 8.5 months and accumulations AFSM ubiquitously (Gupta et al, 
2001). Similar to the human disease, there is widespread neurodegeneration and 
neuroinflammation (Kielar et al, 2007; Macauley et al, 2009). Temporal studies have shown that 
astrocytosis, detectable at 3 months, precedes neurodegeneration, detectable at 5 months. 
Microgliosis and infiltrating immune cells are detectable at 7 months. Overall, there is brain 
atrophy and cortical thinning, with brain weights of PPT1-/- mice at a terminal time point 
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approximately 60% that of normal age-matched animals (Bible et al, 2004). There are significant 
decreases in retinal function measured by ERG and motor dysfunction measured by rotarod 
beginning at 4 months and 5 months, respectively (Griffey et al, 2005; Griffey et al, 2006). 
While mice have been shown to have decreased ERGs, they maintain some visual acuity in the 
early stages of disease (Dearborn et al, 2015; Griffey et al, 2005). Motor function continues to 
decrease over time and PPT1-/- mice are unable to stay on the rotarod past 7 months. 
Spontaneous seizure activity begins at 7 months in 50% of tested animals and occurs in 100% of 
PPT1-/- animals at 7.5 months (Bible et al, 2004).  
While INCL studies have primarily focused on the brain, studies have shown histological 
and pathological defects systemically. Autofluorescent material has been shown to accumulate in 
most tissues outside of the brain, with prevalence in the kidney and spleen (Galvin et al, 2008). 
AFSM has been seen in the liver, bone, eye, and heart. Cardiac defects have been reported in the 
PPT1-/- mouse (Galvin et al, 2008). Echocardiography revealed left ventricular hypertrophy and 
aortic dilatation. It has also been shown that PPT1-/- mice have metabolic dysfunction 
(Woloszynek et al, 2007). Although PPT1-/- mice have relatively normal plasma chemistry, they 
have decreased body weights compared to wild-type mice and have significantly decreased 
adiposity. PPT1-/- mice lose 25% of adiposity and have decreased leptin levels as compared to 
wild-type mice. However, PPT1-/- mice consume more food than wild-type mice and have a 
slower metabolic rate. This suggests that PPT1 deficiency leads to altered energy utilization 
similar to that seen in other LSDs (Woloszynek et al, 2007; Woloszynek et al, 2009). Overall, the 
PPT1-/- mouse recapitulates most of the features of human INCL and is useful as a model for 





Small molecule drugs 
 A number of small molecule drugs have been used to treat human and murine INCL by 
targeting the primary genetic defect through PPT1 mimetics or by targeting the secondary 
disease mechanisms. Two PPT1 mimetics have been developed for pre-clinical studies. The 
development of phosphocysteamine as a small molecule drug for INCL was utilized because it 
functions similarly to PPT1. Phosphocysteamine was shown in vitro to lysosomotrophic and is 
capable of disrupting thioester linkages. The in vitro study of phosphocysteamine showed 
depletion of lysosomal ceroids (GRODs) and showed a decrease in saposin A and D which have 
been shown to accumulate in GRODs (Zhang et al, 2001). This in vitro study prompted the use 
of phosphocysteamine in the PPT1-/- mouse model. Unfortunately, delivery of 
phosphocysteamine showed no improvement of biochemical, histological, or functional 
parameters of INCL (Roberts et al, 2012). Despite this, a clinical trial was conducted combining 
cysteamine bitartrate with N-acetylcysteine (Zhang et al, 2001). The children showed minimal 
improvement in clinical signs of disease as measured by EEG and MRI (Levin et al, 2014).  
 Another PPT1 mimetic, N-tert-butyl-hydroxlamine (NtBuHA), has recently been 
developed. NtBuHA has been shown to similarly deplete lysosomal ceroid accumulation in vitro. 
NtBuHA was shown to cross the blood-brain barrier and minimally improve histological and 
clinical signs of disease in the PPT1-/- mouse (Sarkar et al, 2013). This PPT1 mimetic has not 
yet been tested in clinical trials. 
 Other small molecule drugs have been tested in pre-clinical studies on INCL mice or 
patient fibroblasts. In one study, a stop-codon read-through drug PTC124 was utilized in vitro. 
PPT1 nonsense mutations are one of the most prevalent mutations. PTC124 showed an increase 
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in PPT1 activity and decreased GRODs (Sarkar et al, 2011). In another study, the secondary 
mechanism of disease, neuroinflammation, was targeted using Minozac. Minozac is a small 
molecule inhibitor of proinflammatory cytokines in the brain. This small molecule has been 
shown to attenuate neuronal loss and prevent behavioral deficits in other models of neurologic 
disease (Hu et al, 2007). Given the upregulation of proinflammatory cytokines in INCL, Minozac 
was used in a pre-clinical experiment. Treatment with Minozac resulted in decreased seizures, 
however, it did not improve other clinical parameters (Macauley et al, 2014). There were slight 
improvements in histology with slight decreases in GFAP and CD68 staining, which are markers 
of neuroinflammation. Similarly, there were subtle decreases in cytokine upregulation.   
 
Cross-correction 
 The process of ‘cross-correction’ is the basis for several therapeutic strategies to treat 
soluble lysosomal enzyme deficiencies. It was first proposed by de Duve in 1964 as a treatment 
strategy, and has been refined since its actual discovery in the late 1960s (Deduve, 1964). ‘Cross-
correction’ was a fortuitous discovery by Elizabeth Neufeld and colleagues in 1968 (Fratantoni 
et al, 1968). Discoveries about lysosomal enzymes and their trafficking soon followed detailing 
the mannose-6-phosphate receptor pathway and the modifications of oligosaccharides on 
lysosomal enzymes to mediate lysosomal targeting (Dahms et al, 1989; Kornfeld et al, 1982; 
Natowicz et al, 1979; Varki & Kornfeld, 1980). Briefly, mannose-6-phosphate (M6P) groups are 
attached post-translationally to proteins destined for the lysosome. Via this modification, 
enzymes bind to the M6P/Insulin-growth factor II (M6P/IGFII) receptor in the Golgi and are 
transported through the endosomal pathway. Detachment of the modified proteins in the 
acidified lysosome allows the M6Pr/IGFIIr to recycle to the Golgi or to the plasma membrane 
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(Dahms et al, 1989). Through an undetermined process, possibly exosomes, a small percentage 
of lysosomal enzymes are secreted into the extracellular space. These soluble enzymes can be 
retrieved by neighboring cells through the mannose-6-phosphate or mannose receptor-mediated 
uptake pathways. The endocytosed enzymes are then trafficked back to the lysosome where they 
participate in normal cellular functions (Sands & Davidson, 2006). ‘Cross-correction’ is the 
process underlying stem-cell transplantation, enzyme replacement therapy, and gene replacement 
therapy. Stem-cell transplantation and enzyme replacement therapy have become standard of 
care for a growing number of LSDs. 
 
Cell-mediated Therapy 
 Cell-mediated therapy has been suggested to treat INCL. It is suggested that a limited 
number of engrafted cells are necessary to treat the disease by taking advantage of ‘cross-
correction’. Two methods have been performed pre-clinically, to date. Neural stem cells have 
been transplanted in INCL mice and this procedure has progressed to a phase one clinical trial. 
Neural stem cell transplantation provided increased PPT1 activity, decreased AFSM, and 
delayed motor dysfunction in the mouse (Tamaki et al, 2009). However, the overall effect on 
lifespan was not examined. A clinical trial was initiated in 2005 (Taupin, 2006); however, the 
clinical trial was withdrawn prior to enrollment of patients (NCT01238315). 
 Bone marrow transplantation (BMT) was utilized in a pre-clinical study for INCL. BMT 
has been shown to play a dual role in lysosomal storage diseases of ‘cross-correction’ and 
immunomodulation. In other LSD models, BMT results in varying degrees of efficacy 
(Birkenmeier et al, 1991; Qin et al, 2012; Reddy et al, 2011; Sands et al, 1993), and has become 
standard of care in certain patient populations. In INCL, BMT was shown to have a detrimental 
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effect. INCL mice treated with BMT had a decreased lifespan and impaired motor function 
(Macauley et al, 2012). 
Enzyme replacement therapy 
 Enzyme replacement therapy (ERT) has been shown to be one of the more promising 
candidates for INCL therapy. Similar to cell-mediated approaches, ERT takes advantage of 
‘cross-correction’. Recombinant PPT1 delivered intravenously has been shown to correct the 
systemic histologic phenotype in INCL mice and improve motor function and longevity (Hu et 
al, 2012; Lu et al, 2010). Intrathecal injections of rPPT1 were attempted in PPT1-/- mice to 
target the brain pathology. This study showed that intrathecal injections of rPPT1 were able to 
partially correct histological hallmarks of INCL in the brain, extend lifespan, and improve motor 
function (Lu et al, 2015). However, the improvements observed in both studies were minor and 
rPPT1 had to be administered on a regular basis. 
Gene Therapy Studies  
Gene therapy was first proposed by Friedmann & Roblin in 1972 as a technique to treat 
human genetic diseases (Friedmann & Roblin, 1972).  Since then, a number of pre-clinical gene 
transfer studies have been performed with a variety of viral vectors (e.g. lentivirus, adeno-
associated virus, adenovirus). In the PPT1-/- mouse, gene therapy experiments have been 
performed primarily using adeno-associated viral (AAV) vectors targeting the forebrain, 
hippocampus, and cerebellum. Progressive biochemical, histological, and behavioral 
improvements have been observed as newer generation vectors have been developed. A first-
generation AAV2 vector was utilized to supply a persistent source of PPT1 to the PPT1-/- brain 
via intracranial injections (Griffey et al, 2004). The vector was able to provide localized 
enzymatic activity sufficient to correct the biochemistry and histopathology in the area near the 
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injection site. However, the correction was limited by the diffusion of the AAV2 viral vector and 
‘cross-corrective’ enzyme. An increased dose of the AAV2 vector was able to further improve 
biochemistry, histopathology, and behavior, but the lifespan of the treated mice was not 
significantly extended compared to the untreated PPT1-/- mice (Griffey et al, 2006). In 
subsequent studies, the second-generation AAV2/5 vector was utilized. The intracranial 
AAV2/5-treated mice had greater biochemical, histopathological, and behavioral improvements 
compared to AAV2. Importantly, there was also a significant extension in lifespan (Macauley et 
al, 2012; Macauley et al, 2014; Roberts et al, 2012). This may be explained by the greater 
transduction efficiency and distribution of the AAV2/5 vector in the brain (Burger et al, 2004). 
While the improvements have been significant compared to PPT1-/- mice, overall, they have 
been modest compared to wild-type.  Gene therapy has been shown in pre-clinical studies of 
INCL to be the most effective approach to date. A third-generation vector, AAV2/9, has been 
shown to have a broader distribution in the CNS of animal models and may increase therapeutic 
efficacy in INCL (Dayton et al, 2012; Schuster et al, 2014; Swain et al, 2014). 
 
Goals of the Thesis 
Spinal Cord pathology  
CNS-directed gene therapy was shown to have only modest improvements in lifespan and 
motor function. This was surprising given the nearly normal levels of PPT1 activity in the brain. 
Thus, it was hypothesized that there were regions of the central nervous system that were not 
targeted by brain-directed gene therapy. Therefore, we conducted a more thorough retrospective 
analysis of the AAV2/9- and AAV2/5-treated central nervous system to determine the extent of 
CNS correction. In the retrospective analysis from the treated animals, there was an increase in 
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markers for astrocytosis and neuroinflammation in the spinal cords. A comprehensive temporal 
and spatial analysis of the PPT1-/- spinal cord was conducted in collaboration with Dr. Jonathan 
Cooper, King’s College.  
The retrospective analysis of PPT1-/- animals treated with gene therapy showed that there 
was the accumulation of AFSM throughout the spinal cord and brain stem similar to the PPT1-/- 
brain. Furthermore, there was an increase in GFAP and CD68 staining, which are markers for 
neuroinflammation. The inability of intracranial injections of AAV2/9 to treat the brainstem and 
spinal cord effectively revealed a potential new target for a combinatorial AAV gene therapy-
based approach. Therefore, the first goal of this study was to perform a comprehensive analysis 
of the central nervous system of treated animals to determine the extent of spinal cord disease not 
treated via intracranial AAV vector delivery. The second goal of this study was to determine 
whether targeting both the brain and the spinal cord in PPT1-/- mice would significantly improve 
efficacy. In this study, we transitioned from the second-generation AAV vector (AAV2/5-
hPPT1) to the third-generation AAV vector (AAV2/9-hPPT1) to determine whether a third 
generation vector would provide significantly increased efficacy. We hypothesized that AAV-
based intracranial and intrathecal injection of AAV2/9-hPPT1 would significantly extend the 
lifespan of PPT1-/- mice and improve both clinical and pathological parameters compared to 
either treatment alone.  
 
Multiple cell types involved in INCL pathogenesis 
Multiple studies of INCL neuropathology have shown that there are many CNS cell types 
affected by PPT1 deficiency. Murine INCL progresses sequentially from astrocytosis, to 
neuronal loss, and to microgliosis and immune cell infiltration. This progression has been 
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documented throughout the central nervous system and has been shown to have a profound 
impact on the severity of the disease. When reactive astrocytosis is inhibited by preventing the 
upregulation of intermediate filaments (conducive to astrocyte transition from dormant to 
reactive), the progression of INCL is accelerated. PPT1-/- mice deficient in intermediate 
filaments have a shortened lifespan and an increase in neuroinflammatory markers. Macauley et 
al, (2011) showed that reactive astrocytosis might play a neuroprotective role in INCL 
pathogenesis (Macauley et al, 2011; Shyng & Sands, 2014). Neuronal loss and cortical thinning 
have been well documented in INCL, and their loss is both temporal and spatial. Studies have 
shown that neuronal loss first begins in the thalamus followed by neurodegeneration in the cortex 
and cerebellum (Kielar et al, 2007; Macauley et al, 2009). It has been shown that a subset of 
neuronal proteins which are involved in the regulation of axonal and synaptic vulnerability are 
altered in INCL. Neuronal protein expression changes were present prior to synaptic or axonal 
morphological alterations and followed a similar spatial progression (Kielar et al, 2009). There 
are also changes to receptors and channels involved with neuronal function associated with PPT1 
deficiency (Aby et al, 2013; Kim et al, 2008; Qiao et al, 2007; Tikka et al, 2016; Virmani et al, 
2005; Zhang et al, 2006). Furthermore, PPT1 deficiency has been shown to be involved in blood-
brain barrier maintenance, neuroinflammation, and systemic metabolic and cardiac dysfunction 
(Galvin et al, 2008; Khaibullina et al, 2012; Saha et al, 2008; Saha et al, 2012; Tikka et al, 2016; 
Wei et al, 2011; Woloszynek et al, 2007). While studies have yet to show that PPT1 deficiency 
directly influences myelination, preliminary studies have shown changes in the level and 
organization of myelin (Macauley et al, 2009).  
Overall, this suggests that multiples cell types are involved in INCL disease. This may 
not be surprising since PPT1 is ubiquitously expressed. Unfortunately, our ability to model 
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cellular and metabolic changes in specific cell types in lysosomal storage diseases has been 
lacking. This is due primarily to ‘cross-correction’. It is beneficial to our understanding of INCL 
as well as the development of therapeutics to understand the role of PPT1 in specific cell types. 
This will ultimately guide therapeutic strategies in determining the necessity of correcting all cell 
types or a specific subset of cell types in order to prevent disease.  
 
Tethered PPT1 to the lysosomal membrane 
To understand the cell autonomous roles of specific cell types in INCL, we engineered a 
chimeric lysosomal membrane tethered form of PPT1 using the transmembrane domain/signaling 
peptide of lysosomal-associated membrane protein-1 (LAMP1). The transmembrane 
domain/signaling peptide has been shown to be necessary and sufficient for lysosomal targeting 
of LAMP1, and may be used as a targeting and retention mechanism for soluble lysosomal 
hydrolases (Guarnieri et al, 1993; Marathe et al, 2000). Therefore, the second major goal of this 
thesis was to tether PPT1 to the lysosomal membrane through the transmembrane portion of 
LAMP1 in order to understand the cell autonomous nature of INCL by taking advantage of the 
Cre-loxP system. Therefore, we inserted a loxP-STOP-loxP sequence into the chimeric PPT1-
LAMP1 transgene to achieve cell specificity. The loxP-STOP-loxP region would prevent both 
transcription and translation of our chimeric lysosomal enzyme unless in the presence of Cre 
recombinase. Unfortunately, the transgene appeared to be unstable leading to constitutive and 
ubiquitous expression of PPT1-LAMP1 and an inability to respond to Cre recombinase. 
However, we showed that membrane tethered PPT1 retained enzyme activity and was capable of 
preventing the biochemical, histological, and behavioral phenotype of INCL when expressed 
ubiquitously. Therefore, this study demonstrates a proof-of-principle that tethering PPT1 to the 
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lysosomal membrane could be a viable approach to address questions regarding the role of 
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The neuronal ceroid lipofuscinoses (Batten disease, NCL) are a group of inherited 
pediatric neurodegenerative lysosomal storage disorders (Geraets et al, 2016; Mole & Williams, 
1993). Infantile Batten disease is the most rapidly progressing form of NCL and is caused by 
mutations in the CLN1 gene that codes for palmitoyl-protein thioeseterase-1 (PPT1), a soluble 
lysosomal hydrolase (Kousi et al, 2012; Vesa et al, 1995). PPT1 cleaves fatty acyl chains from 
proteins undergoing lysosomal degradation. Deficiency in PPT1 leads to the pathological 
hallmarks of NCL, which include the accumulation of autofluorescent storage material (AFSM), 
neurodegeneration, and glial activation (Goebel et al, 1995; Haltia et al, 1973a; Haltia et al, 
1973b; Hellsten et al, 1997; Hellsten et al, 1996; Jokiaho et al, 1990; Santavuori et al, 1973; 
Santavuori et al, 1992; Schriner et al, 1996; Syvanen et al, 1997; Vanhanen et al, 1995a; 
Vanhanen et al, 1995b; Vanhanen et al, 1997; Vesa et al, 1995). Though patients are typically 
asymptomatic at birth, by 6 months, INCL patients exhibit progressive degenerative clinical 
signs in vision, motor function, and cognition, which ultimately lead to a shortened lifespan 
(Goebel & Wisniewski, 2004; Haltia et al, 1973a; Haltia et al, 1973b; Santavuori et al, 1973; 
Vanhanen et al, 1995a; Vanhanen et al, 1995b; Vanhanen et al, 1997). Currently, there are no 
effective treatments or cures available for INCL. 
The PPT1-deficient (PPT1-/-) mouse shares most of the biochemical, pathological, and 
clinical signs of human INCL (Gupta et al, 2001). Histopathological characterization of the 
disease in the forebrain and the cerebellum demonstrated progressive AFSM accumulation, 
neurodegeneration, astrocytosis, and neuroinflammation (Bible et al, 2004; Gupta et al, 2001; 
Kielar et al, 2007; Macauley et al, 2009). There is overall brain atrophy with extensive cortical 
thinning concurrent with astrocyte and microglial activation. At a terminal time point, the mass 
of the murine brain is decreased by over 20 percent (Bible et al, 2004). The murine model has 
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functional deficits including, but not limited to retinal dysfunction, loss of motor coordination, 
seizure activity, cardiac insufficiency, and metabolic imbalances (Galvin et al, 2008; Griffey et 
al, 2005; Kielar et al, 2007; Macauley et al, 2009; Woloszynek et al, 2007). PPT1-/- mice 
ultimately have a shortened lifespan with a median lifespan of 8.4 months.  
There have been several pre-clinical therapy studies performed in the PPT1-/- mouse. 
Small molecule drugs that act as PPT1 mimetics such as N-tert-butyl hydroxylamine and 
Cystagon have resulted in minimal improvements (Levin et al, 2014; Sarkar et al, 2013; Zhang et 
al, 2001). Enzyme replacement therapy (ERT) through intravenous or intrathecal routes of 
administration resulted in minor clinical improvements (Levin et al, 2014; Sarkar et al, 2013; 
Zhang et al, 2001). However, the improvements in PPT1-/- neuropathology is only observed 
when treatment is provided at an early stage (i.e. before the establishment of the blood-brain 
barrier) (Hu et al, 2012). To date, the most promising treatment in PPT1-/- mice has been CNS-
directed gene therapy either alone or combined with other approaches (Griffey et al, 2004; 
Griffey et al, 2006; Macauley et al, 2012; Macauley et al, 2014; Roberts et al, 2012). 
Pre-clinical gene therapy experiments have been performed using adeno-associated viral 
(AAV) vectors targeting the forebrain, hippocampus, and cerebellum.  Progressive biochemical, 
histological, and behavioral improvements have been observed as newer generation vectors have 
been developed. First generation AAV2 vectors resulted in improvement in biochemical and 
histological pathology in the regions targeted. However, functional improvement was not 
observed until multiple sites of disease within the INCL brain were targeted by AAV2-hPPT1 
(Griffey et al, 2004; Griffey et al, 2006). Overall, AAV2-hPPT1 increased PPT1 activity, 
reduced AFSM accumulation, and improved histological markers of disease, but did not 
significantly extend the lifespan. The second-generation AAV2/5 vector was shown to have 
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improved neural transduction and distribution in the murine brain (Burger et al, 2004). Besides a 
normalization of PPT1 activity, utilization of AAV2/5-PPT1 showed marked reduction in AFSM 
and pathology, as well as an extension in median lifespan by approximately two months 
(Macauley et al, 2012; Macauley et al, 2014; Roberts et al, 2012). The clinical improvements 
have been modest potentially due to limited distribution of the AAV vector (Aschauer et al, 
2013; Gray et al, 2013). 
A third generation vector, AAV2/9, has been shown to have a broader distribution in the 
CNS in several animal models (Dayton et al, 2012; Schuster et al, 2014; Swain et al, 2014). 
Therefore, in the current study, the AAV2/5-hPPT1 vector used in previous pre-clinical INCL 
gene therapy studies was transitioned to AAV2/9-hPPT1.  
We show that intracranial injection of AAV2/9-hPPT1 provides significantly greater 
efficacy compared to AAV2/5-hPPT1. However, the lifespan was still significantly less than 
wildtype animals despite having nearly normal PPT1 levels in the brain. Therefore, we 
performed a more thorough histological analysis of the central nervous system of treated 
animals. This analysis revealed significant disease throughout the spinal cord that was not 
corrected by intracranial AAV vector delivery. These findings suggested that spinal cord 
pathology could play a significant role in INCL pathogenesis. In collaboration with Hemanth 
Nelvagal and Jonathan Cooper (King’s College, London), we performed a comprehensive 
temporal and spatial analysis of the spinal cord in INCL mice. A brief summary of the findings 
from this study will be presented in this Chapter. These data taken together revealed a new 
region of disease and a possible therapeutic target. Therefore, we targeted the spinal cord with 
intrathecal gene therapy to determine whether AAV-based gene therapy could ameliorate INCL 
pathogenesis. Furthermore, we hypothesized that intracranial plus intrathecal injections of 
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AAV2/9-hPPT1 would significantly extend the lifespan of PPT1-/- mice and improve both 
clinical and pathological parameters compared to either treatment alone. 
Intracranial injection of AAV2/9-hPPT1 resulted in greater therapeutic efficacy than 
intrathecal injection, although both provide significant biochemical, histological, and behavioral 
improvements compared to untreated PPT1-/- mice. Simultaneous treatment of both the brain 
and spinal cord resulted in the greatest efficacy. In fact, targeting these two regions resulted in 
synergistic improvements in lifespan and motor function. These data suggest that the spinal cord 
disease plays a major role in the overall pathogenesis of INCL. These data also identify the 
spinal cord as an important therapeutic target. 
 
Material and Methods 
PPT1-/- and WT mice 
PPT1-/- mice were created by Gupta et al, (2001). Both congenic PPT1-/- and wild-type 
(WT) mice were maintained on a C57Bl/6J background at Washington University School of 
Medicine by MSS. The colonies were maintained separately through homozygous mating. The 
Thy1-YFP PPT1-/- mouse model was generated by crossing the Thy1-YFP reporter mouse (Feng 
et al, 2000)(Tg(Thy1-YFP)16Jrs, The Jackson Lab, Bar Harbor, ME) to the PPT1-/- mouse. The 
reporter mice were maintained as Thy1-YFP+/-, PPT1-/-. All procedures were performed in 
accordance with a protocol approved by the IACUC at Washington University School of 
Medicine.  
 
Recombinant AAV production 
The rAAV2/9-hPPT1 vector used in this study was packaged at the University of North 
Carolina Vector Core. Briefly, the vector contained the CAGGS promoter, human PPT1 cDNA, 
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and a rabbit B-globin polyadenylation signal all flanked by the AAV2 inverted terminal repeats 
(Griffey et al, 2004). Viral titers were 1x10
12
 vg/ml for all injections. 
 
Intracranial and Intrathecal injections 
On postnatal day 1 (PND1) or PND2 PPT1-/- pups received intracranial or intrathecal 
injections with AAV2/9-hPPT1 or AAV2/5-hPPT1 (1x10
12
 vg/ml) using a Hamilton syringe and 
a 30-gauge needle. For intracranial injections, two microliters of virus were injected bilaterally 
into the anterior cortex, hippocampus, and cerebellum as previously described (Griffey et al, 
2006). For intrathecal injections, P1 or P2 PPT1-/- pups were injected in the lumbar region as 
previously described (Elliger et al, 1999; Hawkins-Salsbury et al, 2015). Briefly, 15 microliters 
of virus was mixed with three microliters of sterile Trypan-blue. Fifteen microliters of the 
mixture was injected. A successful injection was confirmed by the appearance of Trypan-blue in 
the tail and the cerebellum. For the combination treatment, both intracranial and intrathecal 
injections were performed on the same day in the same pup.  
 
Treatment Groups 
For the initial AAV2/5 vs AAV2/9 comparison, four groups were generated with 10 mice 
per group: 1) PPT1-/- mice, 2) AAV2/5-hPPT1 intracranial injected PPT1-/- mice (IC-AAV2/5), 
3) AAV2/9-hPPT1-/- intracranial injected PPT1-/- mice (IC-AAV2/9), and 4) wildtype (WT) 
mice. For the combination study, five treatment groups were generated consisting of 22 mice per 
group: 1) PPT1-/- mice, 2) IC-AAV2/9, 3) AAV2/9-hPPT1 intrathecal injected PPT1-/- mice 
(IT-AAV2/9), 4) AAV2/9-hPPT1 intracranial and intrathecal injected PPT1-/- mice (IC/IT-
AAV2/9), and 5) WT mice. Randomly selected mice were analyzed at pre-determined time 
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points (3, 5, 7, and 9 months) for biochemical and histological analyses (n=3 mice/group). 
Experimental and control animals were randomly assigned identification numbers such that the 
person performing the analyses was blind to the genotype and treatment. 
Lifespan 
Longevity was assessed in the treatment and control groups (n=10-11 mice/group). The 
lifespan was determined by death or euthanasia for humane reasons. A Kaplan-Meier lifespan 




Motor function was assessed in the same treated PPT1-/- and control mice (n=10) used 
for longevity using a constant-speed (3 rpm) rotarod beginning at 5 months of age, and every two 
months thereafter as previously described (Dearborn et al, 2015; Griffey et al, 2006). Statistical 
significance was determined using one-way ANOVA at each time point followed by a 
Bonferroni post hoc test. 
 
PPT1 activity and secondary enzyme elevations 
Tissue was collected at pre-determined time points. Three mice per treatment group were 
euthanized via lethal injection (Fatal Plus, Vortech Pharmaceutical, Dearborn, MI). Blood was 
collected from the right ventricle using a 1ml tuberculin syringe and a 26-gauge needle and 
allowed to clot for 15 minutes before centrifugation at 1000xg for 10 minutes. Serum was 
collected and flash frozen. Mice were then transcardially perfused with phosphate-buffered 
saline (PBS) until the liver was cleared of blood. Portions of heart, liver, spleen, kidney, and eye 
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were flash frozen for subsequent biochemical analyses. Additional tissue samples were 
immersion fixed in 4% paraformaldehyde (PFA) in PBS for 24-hr then cryoprotected in 30% 
sucrose solution in Tris-buffered saline (TBS). The spine was removed by cutting at the axis/C1 
and resecting the spine where the spine enters the tail. The spine was fixed and cryoprotected as 
described above. The brain was removed, weighed, and bisected sagittally; the left hemisphere 
was flash frozen while the right hemisphere is fixed and cryoprotected as described above. PPT1 
assays were performed on homogenates from the brain, heart, and liver as previously described 
using the 4-MU-palmitate fluorometric assay and normalized to total protein (van Diggelen et al, 
1999). Secondary elevations of another lysosomal enzyme, β-glucuronidase, were determined as 
previously described using 4-MU-β-D-glucuronide fluorometric assay and normalized to total 
protein (Sands et al, 1994). Significance was determined using a two-way ANOVA followed by 
a Bonferroni post-hoc analysis for all enzyme assays.  
 
Thy1-YFP PPT1 spinal cord analysis 
Thy1-YFP PPT1-/- and Thy1-YFP PPT1+/- mice spinal cords were isolated, fixed, and 
cryoprotected as described above. Spinal cords were sectioned longitudinally at 32 micrometers 
directly onto slides. Confocal images of Thy1-YFP PPT-/- and Thy1-YFP PPT1+/- spinal cords 
were captured at the lumbar region at 10x magnification. Keeping all the parameters identical 
from slide to slide, images were analyzed using ImageJ. Relative fluorescence units were 
calculated by converting the image to a binary black and white image. The number of white 
pixels were calculated and divided by the total pixel area. Three sections were analyzed per 





A histochemical stain for PPT1 activity was performed on sagittal brain sections as 
previously described (Dearborn et al, 2016). Briefly, unfixed tissue was isolated from treated 
mice and immediately embedded in Optimal Cutting Temperature Compound (OCT; Sakura 
Finetek USA, Inc., Torrance, CA) on dry ice. Tissues were cryosectioned at 16 micrometers and 
mounted on Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA, USA). Tissues 
were fixed in 4% paraformaldehyde in PBS on the slides for 20 min at 4°C. Slides were then 
rinsed and equilibrated with 0.2M sodium acetate buffer (pH 4.5). Each slide was covered with 
the histochemical solution overnight at 37⁰C in a humidified chamber. Slides were rinsed with 
water, counterstained with Nuclear Fast Red (Sigma-Aldrich, St. Louis, MO, USA), and 
coverslipped.  
 
Brain and Spinal Cord processing and histological analysis 
Brain processing and analysis was performed as previously described (Macauley et al, 
2012). Briefly, brains from treated and control mice were removed and fixed for 24 hr in 4% 
PFA in PBS. They were then cryoprotected in 30% sucrose in TBS. Brains were sectioned at 40 
micrometers and immunostained for GFAP and CD68, or Nissl. Spinal cords were processed as 
described in Nelvagal et al, (in preparation). Briefly, spinal cords were removed from treated and 
control mice, fixed for 24 hr in 4% PFA in PBS, followed by cryoprotection in 30% sucrose. 
Sections were cut at 40 micrometers and stained with Cresyl Fast Violet (Nissl staining) and 
immunostained for GFAP and CD68. Regional volumes were calculated as previously described 
(Kuhl et al, 2013). Briefly, whole volumes and gray matter were measured in 24 sequential 
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sections. Using the Cavelieri estimation, whole cord volumes and whole gray matter volumes 
were estimated. 
 
Cytokine Profile Analysis 
Cytokine profiling was performed using an Affymetrix multiplex assay through the 
Center for Human Immunology and Immunotherapy Programs (CHiiPS) Immunomonitoring Lab 
(IML) at Washington University School of Medicine. Nine analytes (GRO-α, IFN-γ, IL-10, IP-
10, MCP-1, MCP-3, MIP-2, RANTES, and TNF- α) were measured in brain homogenates of 
treated animals. Treated mice were perfused with PBS prior to removal of the brain. Half of the 
brain was flash frozen and homogenized in 10mM Tris (pH 7.5) 150mM NaCl, 0.2% Triton X-
100, and 1mM DTT, as previously described (Macauley et al, 2014). The homogenate was spun 
at 14,000xg for 1 min, and the supernatant was isolated. Proteinase inhibitor cocktail (P2714, 
Sigma, St. Louis, MO) and PMSF (17 µg/ml, Sigma, St. Louis, MO) were added to the 
supernatant. Samples were flash frozen. For the assay, samples were thawed on ice and 
centrifuged to remove particulates. Samples were then diluted to 10mg of protein/ml. Diluted 
samples were further diluted 1:2 in PBS with premixed beads. The plate was incubated overnight 
on a shaker at 4C. The Affymetrix multiplex plate was run and the data was reported as pg/ml.  
 
Statistical analysis 
Statistical analyses were performed using two-way or one-way ANOVA utilizing the 





Intracranial AAV2/9-hPPT1 is superior to AAV2/5-hPPT1. 
Previous studies have shown that intracranial administration of AAV2/5-hPPT1 
significantly improves the lifespan and motor function in the murine model of INCL (Macauley 
et al, 2012; Macauley et al, 2014; Roberts et al, 2012). Recently, the AAV2/9 vector has been 
utilized in CNS-related disorders due to its improved distribution and transduction efficiency 
(Dayton et al, 2012; Foust et al, 2009). Both IC-AAV2/5 and IC-AAV2/9 treated animals had a 
significant (p<0.001) increase in lifespan compared to untreated PPT1-/- animals. Untreated 
PPT1-/- mice have a median lifespan of 8.4 months. A direct comparison between IC-AAV2/5 
and IC-AAV2/9 administration showed a significant (p<0.001) improvement in median lifespan 
of IC-AAV2/9 animals (13.5 months) compared to IC-AAV2/5 animals (10.6 months) (Figure 
1A). Treatment with IC-AAV2/5 or IC-AAV2/9 significantly increased PPT1 enzyme activity 
levels in the brain to >50% normal (Figure 1B). There was also a reduction of histological 
markers of disease in the brains of both groups (data not shown, Figure 1C).  
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Figure 1. AAV2/9 is superior to AAV2/5 but does not correct the spinal cord. A) Median 
lifespan of PPT1-/- (8.4 months, blue), IC-AAV2/5 (10.6 months, orange), IC-AAV2/9 (13.7 
months, green), and wildtype mice (black). B) PPT1 activity in the terminal brains of IC-
AAV2/5 and IC-AAV2/9 mice (n> 3/group. C) Spinal cord and cortical histology from PPT1-/-, 
WT, and IC-AAV2/9 for AFSM (top) and CD68 (bottom). D) Confocal images of axonal loss in 
spinal cords of PPT1-/- mice. Comparison of Thy1-YFP-PPT1-/- lumbar spinal cord (left) and 
Thy1-YFP-PPT1+/- lumbar spinal cord (right). Mean relative fluorescence (*p=0.013). 
 
Spinal Cord disease in IC-treated PPT1-/- animals 
Although there was an increase in PPT1 activity to >50% normal levels, the increase in 
lifespan was modest. Therefore, a more thorough examination of the treated-animal’s central 
nervous system was conducted. Examination of spinal cord from AAV2/9-PPT1 treated animals 
revealed widespread autofluorescent storage material that was comparable to age-matched PPT1-
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/- mice (Figure 1C). There was also increased microgliosis (CD68) in the treated groups. To 
confirm the presence of spinal cord disease, a Thy1-YFP PPT1-/- reporter mouse model was 
utilized (Castelvetri et al, 2011; Feng et al, 2000). Axonal blebs and gross axonal degeneration at 
7 months are detectable in the INCL spinal cord. There was a significant decrease in axonal 
fluorescence in the lumbar spinal cord of PPT1 deficient mice compared to wildtype (Figure 
1D). These data identified a previously unknown site of disease and uncovered a potential new 
therapeutic target. 
 
Spinal Cord Pathology in INCL 
 Spinal cord pathology has not been characterized in models of INCL animals, and only 
one study has previously reported the possibility of spinal cord disease in INCL patients 
(Santavuori et al, 1974). A temporal examination of the spinal cord from PPT1-/- and WT mice 
revealed a progressive increase in AFSM in the cervical, thoracic, and lumbo-sacral regions 
(Figure 2). A temporal examination of total volume of the spinal cord showed that PPT1-/- mice 
had significantly decreased spinal cord volumes compared to wildtype beginning at two months. 
The difference in volume increases until 3 months then the difference in total volume remains 
essentially constant from three to seven months (Figure 3B, left). Grey matter volume in the 
PPT1-/- mouse was significantly decreased compared to wildtype grey matter volume beginning 
at two months and continues until seven months (Figure 3B, center). The white matter volume is 
significantly decreased in the PPT1-/- spinal cord compared to wildtype from two to seven 
months (Figure 3B, right). 
 Histopathological markers of disease were analyzed in the PPT1-/- spinal cords. There 
was progressive astrocytosis in both the ventral and dorsal horns of the spinal cord in all three 
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regions (cervical, thoracic, and lumbo-sacral) analyzed. There was a significant increase in 
GFAP staining beginning at two months with the percent immunoreactivity increasing until 
seven months (Figure 4A, B).  Similarly, there was progressive microgliosis in the dorsal and 
ventral horns in all regions of the spinal cord analyzed. There was a significant increase in CD68 




Figure 2. Progressive accumulation of autofluorescent storage material. AFSM in the 
cervical (left column), thoracic (middle column), and lumbo-sacral (right column) regions at 1, 3, 
5, and 7 months. 
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Figure 3. Regional Volume measurements of PPT1-/- spinal cords. A) Diagram for 
determining total (left) and grey (right) matter volume (outlined in red). White matter volume is 
determined by subtracting grey matter from total volume. B) Estimated volume for total (left), 
grey (center), and white (right) matter volumes between PPT1-/- (red) and WT (blue) spinal 
cords over time (**p,0.01, *** p<0.001, ****p<0.0001).  
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Figure 4. Progressive astrocytosis in the spinal cord. A) Quantitative GFAP staining in the 
dorsal and ventral horns of PPT1-/- (red) and WT (blue) spinal cords at cervical (top), thoracic 
(middle), and lumbo-sacral (bottom) regions  (**p,0.01, *** p<0.001, ****p<0.0001). B) Image 





Figure 5. Progressive microgliosis in the spinal cord. A) Quantitative CD68 staining in the 
dorsal and ventral horns of PPT1-/- (red) and WT (blue) spinal cords at cervical (top), thoracic 
(middle), and lumbo-sacral (bottom) regions  (**p,0.01, *** p<0.001, ****p<0.0001). B) Image 
of CD68 staining in the PPT1-/- spinal cord at 1, 3, 5, and 7 months. 
 
Figure 6. Diagram of temporal pattern of INCL brain and spinal cord pathology 
 
Summary of Brain and Spinal Cord INCL Pathogenesis 
 As we have shown, there is significant temporal and spatial INCL pathogenesis in the 
spinal cord. Interestingly, spinal cord pathology precedes the brain pathology and shares many 
pathological similarities (Figure 6). This is suggestive of regional specificity of INCL 
progression. For example, significant disease in the thalamus is detectable prior to other regions 
in the brain (Bible et al, 2004). In the brain, there is an accumulation of AFSM and 
astrocytosis/microgliosis beginning at 3 months of age (Bible et al, 2004). Following AFSM 
accumulation and astrocytosis/microgliosis, there is observable neuronal loss and cortical 
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atrophy. As summarized in Figure 6, in the spinal cord, there is significant 
astrocytosis/microgliosis and reduced volume beginning at two months. This precedes the 
neurological disease in the brain by one month. Similarly, neuronal loss precedes INCL disease 
in the brain. INCL has historically been considered a neurodegenerative disease. However, there 
is stagnation in spinal cord volume growth suggesting a role for PPT1 in neurodevelopment. 
Overall, the disease in the spinal cord suggests that this region could be significant in INCL 
pathogenesis and could be a target for AAV-based gene therapy. 
 
Differential PPT1 activity in the brain and spinal cord following intracranial and 
intrathecal AAV2/9-hPPT1 
In order to determine the significance of the spinal cord disease and whether the spinal 
cord could be an effective therapeutic target, PPT1-/- mice were treated with intracranial 
AAV2/9, intrathecal AAV2/9, or a combination of both. Initially, PPT1 activity was measured in 
the brains and spinal cords of animals treated with IC-AAV2/9 or IT-AAV2/9. When the brain 
and spinal cord PPT1 enzyme activity levels at one month were examined from IC-AAV2/9 and 
IT-AAV2/9 mice, PPT1 activity in IC-AAV2/9 brains were significantly higher in the brain than 
WT (Figure 7A). However, PPT1 activity in the IT-AAV2/9 brains were minimal at 
approximately 10% of wildtype. This trend was reversed in the spinal cord with 
supraphysiological levels of PPT1 enzyme activity in IT-AAV2/9 brain but near-PPT1-/- enzyme 
activity in IC-AAV2/9 mice (Figure 7A).  
When determining the temporal patter of expression, PPT1 activity in the wild-type brain 
was approximately 150 nmol/mg/hr throughout the study. In contrast, PPT1 activity was virtually 
undetectable in PPT1-/- mice brains throughout the study. IT-AAV2/9 brains had a small 
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increase in brain PPT1 activity to ~2-5% of wild-type levels. In contrast, IC-AAV2/9 as well as 
the combination IC/IT-AAV2/9 brains had near wild-type to supraphysiological levels of PPT1 
activity (~150-450 nmol/mg/hr)(Figure 7B). Overall, the treatment groups produced a significant 
(p<0.0001) difference in PPT1 activity between three to seven months (two-way ANOVA). 
When comparing treatment groups, there was a significant increase in PPT1 activity in the IC-
AAV2/9 (p=0.0025), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) brains compared to PPT1-
/- brains. IT-AAV2/9 brains had a significant (p=0.0001) albeit small increase in PPT1 activity 
compared to untreated PPT1-/- brains. There was not a significant difference between the IC-
AAV2/9 or IC/IT-AAV2/9 brain PPT1 activities compared to WT (p=0.68, 0.12); however, there 
was a significant difference between WT and IT-AAV2/9 PPT1 activities (p<0.0001).  
A reduction in the secondary elevation of other lysosomal enzymes serves as a 
biochemical surrogate of therapeutic efficacy (Griffey et al, 2004). Overall, the secondary 
elevations of β-glucuronidase in the treatment groups and age of the animals were observed to 
have a significant (p<0.0001) effect in secondary elevations of β-glucuronidase. When 
comparing treatment groups, there was a significant decrease in β-glucuronidase activity in the 
IC-AAV2/9 (p<0.0001), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) animals compared to 
untreated PPT1-/- brains. IT-AAV2/9 brains had a significant (p=0.027) albeit small decrease in 
β-glucuronidase activity compared to untreated PPT1-/- brains. There was a small but significant 
increase in β-glucuronidase activity between the IC-AAV2/9 (p=0.0002), IT-AAV2/9 
(p<0.0001), IC/IT-AAV2/9 (p<0.0001) brains compared to WT β-glucuronidase activity levels 
(Figure 7C).  
Using a recently developed histochemical stain, the brains of experimental and control 
animals were analyzed for the distribution of PPT1 activity. The broad, diffuse blue staining 
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observed in WT brains was not present in the untreated PPT1-/- brain (Figure 8). The IC-
AAV2/9 brains had detectable activity in the cortex and hippocampus with weaker staining in the 
thalamus, cerebellum, and other hindbrain regions. In contrast, in the IT-AAV2/9 brains, an 
increase in staining in the cerebellum and brainstem was observed with little to no staining in the 
forebrain. The IC/IT-AAV2/9 brains had increased staining in both forebrain and hindbrain. 
There was still only low levels of PPT1 detected in the thalamus of IC/IT-AAV2/9 treated mice. 
Figure 7. PPT1 and Secondary enzyme activity in treated animals. A) Analysis of PPT1 
activity at 1 month in the Brain and Spinal Cord following IT-AAV2/9 and IC-AV2/9 injections. 
There was reciprocal PPT1 activity between intrathecal and intracranial injections in the brain 
and spinal cord (**p<0.01, *** p<0.001). B) Temporal analysis of PPT1 activity brain. PPT1 
activity was increased in the brain for IC-AAV2/9 and IC/IT-AAV2/9 to near-WT or 
supraphysiological levels. There was a marginal increase in PPT1 activity in the IT-AAV2/9 
brain (approximately 2-5% WT levels). C) Secondary enzyme levels were normalized in the 
brain. β-glucuronidase levels are increased in the untreated PPT1-/- and IT-AAV2/9 brains. IC-
AAV2/9 and IC/IT-AAV2/9 brains have near WT levels of β-glucuronidase. 
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Figure 8. Histochemical Stain for PPT1 activity. PPT1 activity is depicted in blue. Sections 
were counterstained with nuclear fast red (red). 
  
Intracranial and Intrathecal AAV2/9-hPPT1 reduce histological markers of INCL  
The accumulation of autofluorescent storage material, the histological hallmark of NCL, 
was measured in all the experimental and control animals (Figure 9). A significant increase in 
AFSM was observed in the PPT1-/- brain and spinal cord compared to wildtype. Following 
intracranial administration, there was a significant decrease in AFSM in the M1 (motor cortex) 
and in the VPM/VPL (thalamus), and no decrease in the spinal cord. In contrast, intrathecal 
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administration led to a reduction of AFSM in the spinal cord but not in the brain. Consistent with 
the biochemical and histochemical data, when the brain and spinal cord were simultaneously 
targeted, there was a significant reduction in AFSM in the M1, VPM/VPL, and the spinal cord.  
 
Figure 9. Autofluorescent storage material is reduced in the combination treated animals. 
A) Representative images of AFSM in treated animals. Autofluorescent storage material was 
examined in the S1 barrel field (S1BF) of the somatosensory cortex (top), the VPM/VPL of the 
thalamus (middle), and the ventral horn of the lumbar spinal cord (bottom) of the treated 
animals. B) Quantitative graph of AFSM over time examining the M1 of the motor cortex, 
VPM/VPL of the thalamus, and the lumbar spinal cord. 
 
IC-AAV2/9 and IC/IT-AAV2/9 decrease cortical atrophy 
Profound brain atrophy is another hallmark of INCL. Cortical thickness (Figure 10A) and 
brain weight (Figure 10B) were measured as an indicator of brain atrophy. The PPT1-/- brain 
significantly decreases in weight from 3 months to 7 months when compared to wildtype. The 
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decreasing brain weight was reflected in the significant thinning of the PPT1-/- cortices 
compared to the WT. The IC-AAV2/9 and the IC/IT-AAV2/9 cortices did not show significant 
cortical thinning or a reduction in brain weight as compared to wildtype. However, IT-AAV2/9 
PPT1-/- mice had significant thinning of the cortices, and a progressive decrease in brain weight 
similar to that of untreated PPT1-/-mice. The brains of the IT-AAV2/9 and untreated PPT1-/- 
mice are not significantly different at any time point measured. Overall, both the age of the 
animals and the treatment groups had a significant (p<0.0001) effect on the brain mass. When 
comparing treatment groups, there was a significant increase in brain weight in the IC-AAV2/9 
(p<0.0001), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) animals compared to PPT1-/- 
brains. IT-AAV2/9 brains had a significant (p=0.032) albeit small increase in brain weight 
compared to PPT1-/- animals. There was no difference between the IC/IT-AAV2/9 brain weights 
compared to WT (p=0.862); however, there was a significant albeit small decrease in brain 
weight between IC-AAV2/9 (p=0.040) and WT brains. There was a significant difference 








Figure 10. Cortical atrophy and brain mass is normalized in the combination therapy. A) 
Representative images of cortices from treated animals. Sections were stained with Nissl. B) 
Brain weight from treated animals over time. Brain weights for IC-AAV2/9 and IC/IT-AAV2/9 
brains were essentially normal at all time points examined. IT-AAV2/9 showed a significant 
reduction in brain weight compared to WT brain weight at 7 and 9 months.  
  
Combination therapy reduces neuroinflammation in brain and spinal cord 
Progressive astrocytosis and microgliosis are prominent features of INCL (Kielar et al, 
2007). A significant increase in CD68 and GFAP staining in the PPT1-/- brain and spinal cord 
was observed compared to wildtype (Figure 11A, B & 12A, B). In IC-AAV2/9 brains, there was 
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a significant decrease in CD68 and GFAP staining in the M1 of the motor cortex and the 
VPM/VPL of the thalamus. There was no decrease in CD68 or GFAP staining in the IC-AAV2/9 
spinal cord. In contrast, in IT-AAV2/9, CD68 and GFAP staining were decreased in the spinal 
cord but not in the brain. Similar to the accumulation of AFSM, when the brain and spinal cord 
were simultaneously targeted, there was a reduction in CD68 and GFAP staining in all regions 
examined: M1 of the motor cortex, VPM/VPL of the thalamus, and the lumbar spinal cord.  
Cytokine and chemokine levels in brain homogenates of treated mice and controls were 
measured as a complementary indicator of neuroinflammation. It had been previously shown in 
INCL that there is an increase in cytokine and chemokine production as the disease progresses 
(Macauley et al, 2011; Qiao et al, 2007). There were no significant differences in the levels of 
tumor-necrosis factor-α (TNF-α) or interferon-γ (IFN-γ) between any of the groups (Figure 
13A). In both the CXC motif and CCL motif chemokines, there was a significant increase in 
PPT1-/- brains compared to wildtype brains. Neither IC-AAV2/9 nor IT-AAV2/9 alone 
significantly reduced chemokine levels below that of PPT1-/- brains. There was a slight increase 
above PPT1-/- chemokine levels for IT-AAV2/9 mice in CXCL1, CXCL10, CCL2, and CCL7. 
In the brains of IC/IT-AAV2/9 PPT1-/- mice, there was a significant decrease in all cytokines 




Figure 11. Microgliosis is reduced in the combination treated animals. A) Representative 
images of CD68 staining in treated animals. CD68 staining was examined in the S1 barrel field 
(S1BF) of the somatosensory cortex (top), the VPM/VPL of the thalamus (middle), and the 
ventral horn of the lumbar spinal cord (bottom) of the treated animals. B) Quantitative graph of 




Figure 12. Astrocytosis is reduced in the combination treated animals. A) Representative 
images of GFAP staining in treated animals. GFAP staining was examined in the S1 barrel field 
(S1BF) of the somatosensory cortex (top), the VPM/VPL of the thalamus (middle), and the 
ventral horn of the lumbar spinal cord (bottom) of the treated animals. B) Quantitative graph of 
GFAP over time examining the M1 of the motor cortex, VPM/VPL of the thalamus, and the 
lumbar spinal cord. 
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Figure 13. Cytokine analysis of treated animals at 7 months. A) Pro-inflammatory cytokines. 
B) CXC motif chemokines. C) CC motif chemokines. There were no significant differences in 
TNFα (with the exception of IT-AAV2/9 vs IC/IT-AAV2/9) or IFNγ between any of the groups. 
There was a significant (p<0.05) increase in CXC and CC motif chemokines in PPT1-/- and IT-
AAV2/9. The IC-AAV2/9 chemokine levels had a trend towards normalization to wildtype 
levels except in RANTES. The IC/IT-AAV2/9 chemokine levels were not significantly different 
from wildtype.  
 
Improvements in Motor function and Longevity 
Gross motor function and longevity are robust endpoints used to score the therapeutic 
efficacy of treatments in the INCL mouse. Gross motor function was measured by the latency for 
INCL mice to fall off the rotarod. Wild-type mice remained on the rotarod for 60 seconds for the 
duration of the study (Figure 14A). Untreated PPT1-/- mice displayed significant motor deficits 
starting at 5 months and fell off the rotarod at 7 months with an average latency of ~10 seconds. 
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After 7 months, the untreated PPT1-/- mice were unable to stay on the rotarod. Although IT-
AAV2/9 mice had significantly improved motor function, they began to fall off the rotarod at 7 
months with an average latency to fall of 48 seconds and continued to decline until 11 months 
(latency ~18 seconds). IC-AAV2/9 mice had significantly improved motor function compared to 
IT-AAV2/9 animals. IC-AAV2/9 mice began to fall off the rotarod at 9 months with an average 
latency to fall of ~58 seconds and continued to decline until 13 months (~14 seconds). The 
combination IC/IT AAV2/9 mice had significantly improved motor function compared to either 
IC-AAV2/9 or IT-AAV2/9 mice and displayed significant motor deficits starting at 15 months 
with an average latency of ~50 seconds. The average latency remained constant at 17 months but 
declined at 19 months to ~40 seconds. By 21 months, the remaining IC/IT-AAV2/9 mice were 
unable to stay on the rotarod (Figure 14A).  
Untreated PPT1-/- mice had a median lifespan of 8.4 months (Figure 14B). IT-AAV2/9 
mice have a significant extension in median lifespan to 11.8 months and the IC-AAV2/9 mice 
had a median lifespan of ~13.6 months. The IC/IT-AAV2/9 mice had a dramatic and significant 
extension in median lifespan to 19.3 months, with the longest-lived mouse at 22 months. Only 








Figure 14. Functional and behavioral phenotype is improved with the combination therapy. 
A) Rotarod test for motor function. The PPT1 -/- mice (blue) were unable to stay on the rotarod 
past 7 mo. IT-AAV2/9 mice (red) showed motor deficits at 7 month and could not stay on past 
11 mo. The IC-AAV2/9 mice (green) showed deficits at 9 mo and could not stay on past 13 mo. 
The combination IC/IT-AAV2/9 mice (purple) showed deficits at 15 mo and could not stay on 
past 19 mo. B) Lifespan curve. The median lifespan for PPT1-/- mice (blue) was 8.4 mo. IT-
AAV2/9 mice (red) had an extension in lifespan of 11.3 mo (+3 mo). IC-AAV2/9 mice (green) 
had an extension in lifespan of 13.7 mo (+5.3 mo). The combination IC/IT-AAV2/9 mice 





To date, pre-clinical gene therapy studies for INCL have focused on the delivery of PPT1 
to the brain (Griffey et al, 2004; Griffey et al, 2006; Macauley et al, 2012; Macauley et al, 2014; 
Roberts et al, 2012). Gene therapy studies utilizing a second-generation AAV vector (AAV2/5) 
have shown that persistent delivery of PPT1 can significantly extend the lifespan, decrease 
histological markers of disease and improve motor function in INCL mice (Macauley et al, 2012; 
Macauley et al, 2014; Roberts et al, 2012). In the current study, we show that the third-
generation AAV vector, AAV2/9, is superior to AAV2/5. Intracranial injection of AAV2/9-
hPPT1 nearly normalized PPT1 activity, and reduced the secondary elevations of another 
lysosomal enzyme in the brain. However, IC-AAV2/9 mice still had a significantly shortened 
lifespan compared to their wild-type littermates. We hypothesized that the distribution of PPT1 
was not sufficient to treat the entire CNS.  
A more thorough analysis of the CNS from a separate cohort of IC-AAV2/9 mice showed 
no reduction of AFSM accumulation or neuroinflammation in the spinal cord. The persistent 
spinal cord disease could partially explain the limited efficacy in this and other studies when 
gene therapy was limited to the brain. This study and previous studies have shown that the brain 
mass of PPT1-/- mice receiving intracranial injection of an AAV vector does not significantly 
decrease until near terminal; whereas the brain mass of PPT1-/- animals begin decreasing at 5 
months of age (Macauley et al, 2014; Roberts et al, 2012). This suggests that the spinal cord 
disease may play a significant role in the overall pathogenesis of INCL. The neurological disease 
observed in the spinal cord of treated PPT1-/- mice is corroborated by the appearance of axonal 
blebs and axonal degeneration using the Thy1-YFP PPT1-/- reporter mouse. The Thy1-YFP-
PPT1-/- reporter model will be a useful tool for the characterization of INCL spinal cord disease 
and for evaluating efficacy.  
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A comprehensive temporal and spatial examination of the PPT1-/- murine spinal cord 
showed progressive AFSM accumulation and neuroinflammation beginning at 2 months of age 
(Nelvagal et al, in preparation). The disease in the spinal cord affects both the grey matter and 
white matter tracts. Interestingly, the total volume of the spinal cord in PPT1-/- animals stayed 
constant from one month to seven months whereas the wildtype volumes increased. This trend 
was similar for both the grey and white matter volumes. This suggests a potential 
neurodevelopmental defect in the PPT1-/- animals that has not been previously characterized. In 
the characterization of the INCL spinal cord pathology, astrocytosis and microgliosis were 
significantly increased beginning at two months of age. This precedes the onset of disease in the 
brain which begins at three months of age (Kielar et al, 2007). This finding redefines the age of 
onset for INCL CNS pathology (Figure 6). Collectively, these data suggest that the spinal cord 
could be an effective therapeutic target. Interestingly, a previous study showed that intrathecal 
injections of recombinant PPT1 over three consecutive days was able to extend the lifespan, 
improve motor function, and modestly decrease histological signs of disease in the spinal cord 
(Lu et al, 2015). It is possible that some of the efficacy was due to decreasing the spinal cord 
disease.  
Based on these data, we performed a more comprehensive study targeting the spinal cord 
alone and in combination with brain-directed gene therapy. Similar to previous studies, 
intracranial AAV mediated gene therapy using an AAV2/9 vector resulted in significantly 
increased longevity, improved motor function, and decreased pathology in the brain. We 
discovered that there was no improvement observed in the spinal cord disease following brain-
directed gene therapy. While intrathecal AAV2/9 gene therapy alone resulted in decreased 
pathology in the spinal cord, a significant extension in lifespan, and improved motor function, 
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the pathology in the brain was not improved. These results are consistent with the reciprocal 
pattern of enzyme activity in those areas. This small increase in enzymatic activity in the brain 
following intrathecal injection is not surprising given the limited distribution of AAV2/9 when 
delivered intrathecally (Schuster et al, 2014).  
Surprisingly, no significant differences in cytokine or chemokine levels in the brain 
between the intracranial treated animals and their PPT1-/- littermates were detected even though 
there was a decrease in CD68 and GFAP staining. Cytokine and chemokine levels were 
measured in whole brain homogenates. Both the intracranial and intrathecal injections target 
specific regions of the CNS. Therefore, INCL disease is still progressing in the CNS regions not 
targeted by either therapy. It is plausible that cytokines/chemokines from the unresponsive 
regions distribute throughout the brain. Not surprisingly, there were no decreases in 
cytokine/chemokine levels in IT-AAV2/9 brains. Cytokine and chemokine levels were only 
decreased when both the brain and spinal cord were targeted. This is consistent with the 
biochemical and histological findings. 
The different clinical responses of animals treated with either IC- or IT-AAV2/9 provide 
important insights into the progression of INCL. As mentioned above, the significance of the 
spinal cord disease to the overall pathogenesis was not known. IT-AAV2/9 corrects much of the 
pathology in the spinal cord but has little effect on the brain. The fact that motor function was 
improved and the lifespan was increased when histological correction was limited to the spinal 
cord suggests that this aspect of INCL is clinically significant. However, it is unclear if IT-
AAV2/9 resulted in correction of other, yet unknown, aspects of INCL as well. For example, it is 
not known if INCL affects the peripheral nervous system (PNS). Intrathecal injection of AAV 
vectors has been shown to deliver transgene products to the sciatic nerve (Federici et al, 2012; 
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Jacques et al, 2012; Schuster et al, 2014; Vulchanova et al, 2010). It is possible that IT-AAV2/9 
is affecting the PNS in INCL. These data also demonstrate that the brain is the most severely and 
acutely affected region of the CNS, since limiting therapy to the brain is clearly more effective 
than targeting the spinal cord. 
When the intracranial and intrathecal injections are combined, there is a dramatic and 
significant extension in lifespan and improvement in motor function compared to either therapy 
alone. This is most likely due to the broader distribution of the AAV-hPPT1 vector in the CNS. 
Taken together, these data suggest that it will be necessary to treat both the spinal cord and brain 
disease to achieve maximum efficacy. Interestingly, these data also show that targeting both 
regions results in synergistic improvements. For example, if the modalities were simply additive, 
the extension in lifespan would be approximately 16.7 months rather than the 19.3 months 
observed. Similarly, the improvement in motor function also suggests a synergistic effect. The 
age at which IC/IT-AAV2/9 mice begin to fall off the rotarod (15 months) is greater than the 
sum of the increases observed with the IT-AAV2/9 (7 months) or IC-AAV2/9 (9 months) mice.  
Although the combination therapy significantly improves lifespan and motor function, 
the IC/IT-AAV2/9 mice have a reduced lifespan compared to their wildtype littermates. These 
data suggest that the IC/IT-AAV2/9 mice may either be succumbing to disease outside of the 
central nervous system or that the minimal correction of the thalamus/mid-brain is not sufficient 
to prevent neurodegeneration. These data suggest that an intracranial or intrathecal 
administration route alone is not sufficient to correct the entire CNS (Rosenberg et al, 2014). It 
has been shown that there is cardiac dysfunction in models of Batten disease and INCL (personal 
communication with Dr. Jonathan Cooper, (Galvin et al, 2008)) as well as systemic metabolic 
defects (Woloszynek et al, 2007). Targeting these secondary disease modalities using small 
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molecule drugs or recombinant PPT1 in combination with gene therapy may further extend the 
lifespan and quality of life for treated-INCL mice. Simultaneously targeting multiple pathogenic 
mechanisms or different diseased compartments has proven effective in INCL (Macauley et al, 
2012; Macauley et al, 2014; Roberts et al, 2012) and other LSDs (Biswas & LeVine, 2002; 
Hawkins-Salsbury et al, 2011; Hawkins-Salsbury et al, 2015; Jeyakumar et al, 2001; Lee et al, 





































This chapter is adapted from the following manuscript: 







 Soluble lysosomal enzymes are translated and glycosylated in the endoplasmic reticulum 
then transported to the Golgi apparatus where terminal mannose residues are phosphorylated at 
the six position (M6P). Binding to the M6P /IGF II receptor in the Golgi targets the 
phosphorylated enzymes to the lysosome through the endolysosomal pathway. The enzyme-
receptor complex uncouples at acidic pH releasing the enzyme for proper lysosomal activity. It 
has been shown that soluble lysosomal enzymes are secreted from a parent cell and can be 
captured by neighboring cells via the M6P/IGFII receptor on the plasma membrane (Barton & 
Neufeld, 1971; Cantor & Kornfeld, 1992; Hickman & Neufeld, 1972; Neufeld & Fratantoni, 
1970). Trafficking of the secreted enzymes to the neighboring lysosome allows enzymatic 
functionality to be restored (Dahms et al, 1989; Neufeld, 1980; Neufeld, 2006; Verkruyse & 
Hofmann, 1996; Willingham et al, 1981). This inter-cellular trafficking of lysosomal enzymes, 
termed ‘cross-correction’, forms the basis of therapeutic approaches using cell-based, virus-
based, or enzyme replacement therapies. While ‘cross-correction’ enhances treatment, it prevents 
the cell-autonomous study of enzyme deficiencies in lysosomal storage diseases (Sands, 2013; 
Sands & Davidson, 2006). 
 For this study, we utilized the soluble lysosomal hydrolase palmitoyl-protein 
thiosesterase-1 as a model enzyme to study cell autonomy in a lysosomal storage disorder. In 
humans, deficiency of PPT1 results in infantile neuronal ceroid lipofuscinosis (INCL), a 
progressive neurodegenerative disease (Hofmann et al, 1999; Vesa et al, 1995). 
Histopathological characterization of PPT1 deficiency reveals an accumulation of 
autofluorescent storage material (AFSM), neuronal death, glial activation, and 
neuroinflammation. This pathology results in progressive clinical deficits in vision, motor 
function, and cognition. A PPT1-deficient mouse model closely mimics human INCL (Bible et 
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al, 2004; Gupta et al, 2001). Understanding the role of specific cell types in INCL pathology may 
lead to an improvement in targeted therapeutics in humans. Using proteomics and metabolomics, 
studies have shown that PPT1 deficiency leads to alterations in global cellular and metabolic 
expression profiles. However, modeling cellular and metabolic profile changes in specific cell 
types has been lacking due to ‘cross-correction’ (Aby et al, 2013; Scifo et al, 2015; Tikka et al, 
2016). By sequestering PPT1 in individual cells, we may begin to understand the role of specific 
cell types in disease progression, as well as the interactions of PPT1 sufficient and deficient cells 
in a hypothetical therapeutic environment. 
 To overcome ‘cross-correction’, we have engineered a chimeric, lysosomal membrane-
tethered form of PPT1 using the transmembrane domain/signaling peptide of lysosomal-
associated membrane protein-1 (LAMP1). The transmembrane domain/signaling peptide has 
been shown to be necessary and sufficient for lysosomal targeting of LAMP1, and may be used 
as a targeting and retention mechanism for secreted lysosomal hydrolases (Guarnieri et al, 1993; 
Rohrer et al, 1996). A similar approach has been used to create a milder form of Neiman-Pick 
A/B disease (acid sphingomyelinase (SMase) deficiency) (Marathe et al, 2000). In our model, we 
created a chimeric form of PPT1 that is tethered to the lysosomal membrane and would be 
expressed in a cell-specific manner (PPT1-LAMP1). To accomplish cell-specificity, we 
employed a genetic approach by inserting a loxP-STOP-loxP sequence into the transgene that 
would prevent both transcription and translation of PPT1-LAMP1 unless in the presence of Cre 
recombinase.  
We show here that membrane tethered PPT1 retains enzyme activity and is capable of 
preventing the biochemical, histological, and behavioral phenotype of INCL when expressed 
ubiquitously in vivo. Unfortunately, the transgene rearranged leading to Cre unresponsiveness, 
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and unregulated and ubiquitous PPT1-LAMP1 expression. Nonetheless, this study demonstrates 
a proof-of-principle that this general methodology is a viable approach to address questions 
regarding the role of specific cell types in the progression of INCL. 
 
Materials and Methods 
PPT1-LAMP1 transgene 
A diagram of the PPT1-LAMP1 transgene is shown in Figure 1. The transgene includes 
the promoter and first intron of the chicken β-actin gene, a LoxP-STOP-LoxP sequence from 
pBS302 (Addgene, Cambridge, MA), the human PPT1 cDNA genetically linked to a 120bp 
sequence encoding the transmembrane domain and lysosomal localization sequence of LAMP1, 
a six-glycine linker region, followed by a rabbit β-globin polyadenylation signal.  
 
Generation of the PPT1-LAMP1 transgenic mouse  
Transgenic mice were generated by microinjection of the transgene into C57Bl/6 
embryos. This service was performed by the Transgenic Knockout Microinjection Core at 
Washington University School of Medicine. Founder lines were identified by PCR using primers 
flanking the PPT1-LAMP1 junction. Germline founder lines were identified by breeding 
transgene positive mice to PPT1-/- mice. Germline transgene transmission was identified using 
the aforementioned PCR primers. When possible, the transgenes were fixed on the PPT1-/- 
background. Congenic C56Bl/6 wild-type mice were used as controls. 
 
Lentiviral production of PPT1-LAMP1 
A 3
rd
 generation SIN lentiviral vector was created for in vitro experiments (Dull et al, 
1998; Zufferey et al, 1998). Briefly, the transfer plasmid contained the phosphoglycerate kinase 
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(PGK) promoter, the target gene, a SV40 poly(A) site, and a puromycin resistant cassette. The 
target gene contained wild-type PPT1 or PPT1-LAMP1. The negative-control, empty lentiviral 
vector did not contain a target gene. The transfer plasmid was transiently transfected in 
combination with pMD-Lg/pRRE, pRSV-Rev, and pMD2.G plasmids into HEK293T cells by 
calcium-phosphate transfection. Media containing lentivirus was collected and concentrated 
using ultracentrifugation as previously described (Dull et al, 1998; Zufferey et al, 1998). 
Lentiviral titers were assessed using serial dilutions and puromycin selection.  
 
Transwell experiment 
Cross-correction experiments were performed using a transwell system (Corning, 
Corning, NY). Briefly, PPT1-/- cells were plated on the bottom well, transduced for 24 hours, 
then exposed to puromycin after 72 hours post-transduction. The bottom well cells were allowed 
to become confluent. Untransduced PPT1-/- cells were plated on the transwell inserts in a 
separate dish, and were transferred into the experimental plate. Three days post-incubation, cells 
and media were collected for PPT1 enzyme activity. Cells were lysed in 10mM Tris pH 7.5, 
150mM NaCl, 0.2% Triton X-100 via three freeze-thaw cycles. Cells were centrifuged and 
supernatant collected for enzyme activity. Cross correction experiments using primary dermal 
fibroblast cell cultures from one of the transgenic animals were similarly performed with the 
primary cells being plated on the bottom wells. 
 
RNA isolation, RT-PCR, and Sequencing 
RNA was isolated from brain, heart, and liver using TRIzol (Thermo Fischer, Waltham, 
MA) as described. Briefly, samples were homogenized in TRIzol. RNA was isolated, and cDNA 
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was generated using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fischer, 
Waltham, MA). RT-PCR was performed using primers flanking the 6-glycine region. The 
forward primer was in the PPT1 sequence and the reverse was in the LAMP1 sequence. DNA 
sequencing was performed using the Protein and Nucleic Acid Chemistry Laboratory using 
Sanger di-deoxy sequencing. The sequencing primers flanked the loxP-STOP-loxP sequence. 
qPCR was performed on genomic DNA. Standards for copy number were generated from serial 
dilutions of the stock PPT1-LAMP1 plasmid. Quantitation for copy number was generated as 
previously described (Joshi et al, 2008). 
 
SDS-PAGE/Western Blot 
To confirm expression of PPT1-LAMP1 protein, lentiviral transduced cells or primary 
cell lines derived from a transgenic animal and control lines were isolated and homogenized in 
50mM Tris-HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 150mM NaCl, and 2mM EDTA (RIPA buffer). Cells were spun at 14000xg for 1 min 
and the supernatant was collected. The cell supernatant was diluted to 2µg protein/ul and 30ug of 
protein were loaded onto 12% SDS-PAGE gels (Bio-Rad, Hercules, CA). Protein was transferred 
onto PVDF (Porex Filtration Group, Fairburn, GA) membrane and probed for human PPT1 
(Abcam 89022; 1:1000) or the cytoplasmic domain of LAMP1 (Sigma L1418; 1:1000). 
Secondary antibodies for mouse-horseradish peroxidase (HRP) or rabbit-HRP were used. Pierce 
ECL Western Blotting Substrate (ThermoFisher, St. Louis, MO) was used to detect the 
antibodies.  
 
PPT1 Enzyme Activity and Secondary Enzyme Elevations 
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Three mice each from transgenic and control groups were euthanized via lethal injection. 
Mice were transcardially perfused with phosphate-buffered saline (PBS) until the liver was 
cleared of blood. Portions of visceral organs (heart, liver, spleen, kidney, eye) were flash frozen 
for subsequent biochemical analyses. Additional tissue samples were fixed in 4% 
paraformaldehyde in PBS solution for 24-hr fixation then cyroprotected in 30% sucrose solution 
in Tris-buffered saline (TBS). The brain was removed, weighed, and bisected sagittally; the left 
hemisphere was flash frozen while the right hemisphere was fixed/cyroprotected. PPT1 assays 
were performed on the brain, heart, and liver as previously described using the 4-MU-palmitate 
fluorometric assay and normalized to total protein (Griffey et al, 2004). Secondary elevations of 
β-glucuronidase was determined using 4-MU-β-D-glucuronide fluorometric assay and 
normalized to total protein as previously described (Roberts et al, 2012). Significance was 
determined using a two-way ANOVA followed by a Bonferroni post-hoc analysis for all  
enzyme assays.  
 
Immunofluorescence 
Immunofluorescence was performed as previously described (Hawkins-Salsbury et al, 
2013). Briefly, cells were plated on poly-lysine coated coverslips. Cells were fixed then 
permeabilized with a 0.01% Triton X-100 in TBS solution. After blocking with 5% normal goat 
serum in TBS, cells were stained for human PPT1 (rabbit anti-rat), the cytoplasmic domain of 
Lamp1 (rat anti-mouse), and DAPI. Primary antibodies were detected with Alexa Fluor 488 
(anti-rat) and 555 (anti-rabbit). 
 
Autofluorescent Storage Material 
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AFSM was imaged as previously described (Griffey et al, 2004). Briefly, fixed and 
cryoprotected tissue was frozen in Optimal Cutting Temperature compound (OCT, Tissue-tek, 
VWR, Radnor, PA). Twelve-micrometer sections were cut and placed onto Superfrost slides. 
The slides were allowed to dry for 24 hrs at room temperature. The OCT was washed off using 
diH2O, and allowed to dry. Slides were coverslipped using Vectashield Antifade mounting 
medium (Vector Labs, Burlingame, CA). Sections were then imaged using confocal microscopy. 
 
Lifespan, Rotarod, and Electroretinography 
Longevity was assessed in control groups and transgenic mice (n=10-11 mice/group). 
The lifespan study was determined by death or euthanasia at one year. A Kaplan-Meier lifespan 
curve was used to measure survival and significant differences were determined using a log-rank 
analysis (p<0.05). 
Transgenic and control mice (n=10) were tested on a constant-speed rotarod (3 rpm) at 7 
months as previously described (Dearborn et al, 2015). Statistical significance was determined 
using one-way ANOVA at each time point followed by a Bonferroni post hoc test. 
Electroretinography (ERG) was performed by the Vision Core at Washington University 
in St. Louis as previously described (Griffey et al, 2005; Heldermon et al, 2007). Briefly, mice 
were dark-adapted for mixed rod/cone ERG for a minimum of 2 hours or light adapted for 20 
minutes for pure cone ERG measurements. Mice were then anesthetized. A recording electrode 
was placed on the cornea and a reference electrode was inserted subcutaneously behind the ear. 
Mice were exposed to flashes of light and the a- and b-waves were recorded using the UTAS-E-
3000 LKC testing and analysis system (LKC Technologies, Gaithersburg, MD). b-wave 




Lysosomal Membrane-Tethered PPT1 
PPT1 is a soluble lysosomal hydrolase that can be secreted then endocytosed by 
neighboring cells. Studying PPT1 function in a cell autonomous manner is difficult due to ‘cross-
correction’. Therefore, we generated a tethered form of PPT1 by anchoring the enzyme to the 
lysosomal membrane (Figure 15A). We genetically engineered the tethered PPT1 such that the 
enzyme is within the lumen of the lysosome and that the C-terminus of PPT1 is tethered to the 
transmembrane domain and C-terminus of the lysosomal acidic membrane protein-1 (LAMP-1) 
via a six glycine linker (PPT1-LAMP1). Conceptually, the six-glycine linker region should not 
have steric hindrance nor disallow PPT1 to function properly. The transmembrane domain and 
C-terminus of LAMP-1 is a lysosomal membrane protein and has been shown to be targeted to 
the lysosome via the YQTI amino-acid motif (Figure 15B).  
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Figure 15. Mockup and Sequence of PPT1-LAMP1. A) Ribbon diagram of PPT1-LAMP1. 
PPT1 is in the lumen of the lysosome (globular structure). It is connected to the C-terminus and 
transmembrane domain of LAMP1 (pink) by a six glycine linker (light blue). B) Amino acid 
sequence of PPT1-LAMP1. The human PPT1 sequence (green) is genetically tethered to the 
transmembrane domain and C-terminus of LAMP-1 (pink) by the six-glycine linker (light blue). 
The lysosomal targeting motif is underlined.  
 
PPT1-LAMP1 function in vitro 
PPT1-/- fibroblasts were transduced in vitro with lentiviral constructs containing hPPT1-
LAMP1, WT-hPPT1, or a negative-control empty vector. Lysosomal localization of PPT1-
LAMP1 was confirmed using immunofluorescence by staining against human PPT1 and LAMP-
1 (Figure 16A). A western blot was performed on protein homogenates from these cells and 
showed that there was an increase in molecular weight of the hPPT1-LAMP1 (~40 kDa) 
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compared to the wildtype human PPT1(~32-36 kDa). This was consistent with the additional 
molecular weight of the LAMP1 transmembrane domain and six-glycine linker (~5 kDa). 
Blotting against the C-terminus of LAMP-1, both the endogenous LAMP1 (~120 kDa) and a 
signal at ~40 kDa were detected. This was the same molecular weight as PPT1-LAMP1 detected 
with the anti-PPT1 antibody (Figure 16B).  
To confirm that PPT1-LAMP1 retained enzyme activity and was not secreted, a transwell 
experiment was performed where the bottom well contained the lentiviral-transduced cells and 
the transwell contained untransduced PPT1-/- cells. There was little to no PPT1 activity in cell 
transduced with the empty vector (Figure 15C). Following transduction with wildtype PPT1, 
significantly higher PPT1 activity (~400 nmol/µg/hr) was detected compared to the empty vector 
cells. After transduction with the PPT1-LAMP1 vector, the level of PPT1 activity in the 
transduced cells was comparable to the WT-PPT1 transduced cells. Lastly, PPT1-LAMP1 was 
not secreted from the transduced cells. In the wild-type hPPT1 transduced wells, there was an 
increase in PPT1 activity in the transwell cells (~5% of wild-type levels). However, in the PPT1-
LAMP1 transduced wells, there was little to no detectable activity in the transwell cells from the 
PPT1-LAMP1 well. In the negative control, as expected, PPT1 enzymatic activity was 




Figure 16. In vitro characterization of PPT1-LAMP1. A) Immunofluorescence of PPT1 
(green, left) and LAMP-2 (red, center). Co-localization of PPT1 and LAMP2 is in yellow (right). 
B) Expression of PPT1-LAMP1 in vitro. PPT1-/- cells were transduced with lentivirus 
containing hPPT1-LAMP1 or hPPT1. The left panel is probed for anti-hPPT1. hPPT1 has a 
predicted molecular weight of ~32 and 36 kDa, and hPPT1-LAMP1 is predicted at ~40 kDa. The 
right panel was probed for the C-terminus of LAMP-1. LAMP-1 signal was detected in the lane 
from hPPT1-LAMP1 transduced cells. C) Transwell experiment for ‘cross-correction’. Cells 
were transduced with empty, WT-PPT1, or PPT1-LAMP1 lentiviral vectors. There was a 
significant increase in enzyme activity in the WT-PPT1 compared to empty. WT-PPT1 cells and 
PPT1-LAMP1 cells had similar levels of activity. There was a significant increase in PPT1 
activity in the transwell inserts in the WTPPT1 transwell compared to Empty and PPT1-LAMP1 
transwells (p<0.05).  
 
Generation of a PPT1-LAMP1 transgenic animal 
To study the role of specific cell to the pathogenesis of INCL in vivo, transgenic animals 
harboring the PPT1-LAMP1 transgene were generated. For cell-specificity, we included a loxP-
STOP-loxP sequence within our transgene (Figure 17A). In vitro transfection of PPT1-/- cells 
with a Cre-recombinase plasmid or the transgene-containing plasmid alone resulted in no 
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increase in PPT1 activity levels compared to PPT1-/- cells. However, when transfected together, 
there was a significant increase in PPT1 activity to near WT-PPT1 activity levels (Figure 17B). 
This confirmed that the transgene-containing plasmid was Cre-responsive.  
PPT1-/- animals harboring the transgene were generated after confirmation of in vitro 
feasibility. Transgene-positive founder animals were identified by PCR analysis for the PPT1-
LAMP1 junction (Figure 18A, B). Eight transgene-positive animals were identified. Five founder 
lines demonstrated germ-line transmission. However, three founders were unable to establish 
productive colonies. Two founders (Founder #38 and #42) were able to generate colonies. 
Founder #38 did not express PPT1-LAMP1 in the presence or absence of Cre-recombinase. 
Surprisingly, a PPT1 enzymatic assay of Founder #42 (F42) brain resulted in supraphysiological 
levels of PPT1 activity in the absence of Cre recombinase (data not shown). While unfortunate, 
F42 could be utilized as a proof-of-principle transgenic model of sequestered PPT1. 
Figure 17. Generation of a cell-specific transgene. A) Structure of the transgene. LoxP sites 
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are shown in triangles. B) The transgene was first tested in vitro. There was not a significant 
increase in PPT1 activity in the PPT1-/- cells transfected with the transgene alone or the Cre-
containing plasmid alone. There was a significant increase in PPT1 activity when the transgene 
and the Cre-containing plasmid were transfected together. pCAGGs-hPPT1 plasmid was used as 
a transfection control (p<0.05).   
 
Founder #42 analyses 
Molecular and biochemical characterization of F42 revealed a possible spontaneous 
recombination, and expression of the PPT1-LAMP1 transcript and protein. Further 
characterization of the transgene was performed using primers flanking the loxP-STOP-loxP 
sequence (Figure 18A). Surprisingly, a band of approximately 260bp was detected. This 
fragment was consistent with recombination of the loxP sites (Figure 18C). Further DNA 
sequencing of the fragment confirmed Cre-independent recombination. Approximate copy 
numbers were calculated using quantitative PCR. The qPCR confirmed an approximate 11 
transgene copies per genome. 
Using RT-PCR, PPT1-LAMP1 mRNA was detected in the brain, heart, and liver of F42 
mice but was undetectable in wildtype or PPT1-/- mice (Figure 19A). Western blot analysis was 
performed on primary dermal fibroblasts to confirm the presence of PPT1-LAMP1. In F42 
primary fibroblasts, a protein of ~36-40 kDa was detected with an anti-hPPT1 antibody (Figure 
19B, left). Similarly, a protein was detected at ~40 kDa with an anti-LAMP1 antibody directed 
towards the C-terminus domain (Figure 19B, right). This was consistent with the aforementioned 
in vitro studies that reflected the increase in size due to the addition of the LAMP-1 C-terminus 
and transmembrane domain. Similarly sized proteins were not detected in the primary dermal 
fibroblasts from murine PPT1-/- and wild-type mice. However, the PPT1 signal was detected in 
human fibroblast cultures. The two bands likely correspond to unglycosylated (lower band) and 
glycosylated PPT1 (Das et al, 2001; Lyly et al, 2007). There was a faint band in the F42 
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homogenates that migrated at approximately the same position as the unglycosylated PPT1 in the 
human fibroblasts. With further characterization of F42, dermal fibroblasts using a transwell 
system showed that PPT1-LAMP1 does not ‘cross-correct’ (Figure 19C). Approximately 10 
nmol/µg/hr PPT1 activity was detected in the transwell cells exposed to media from the wild-
type cells. In contrast, no PPT1 activity was detected in the transwell cells exposed to media 
from the F42 cells even though F42 dermal fibroblasts had ~6-fold greater PPT1 activity 
compared to wildtype cells.  
Figure 18. Generation of transgenic animals and identification of loxP site recombination. 
A) Structure of the transgene and position of primers. Primers used for the identification of 
recombination are shown in red. Primers used for identification of transgenic animals are shown 
in forward: yellow and reverse: red. Primers used for RT-PCR are shown in blue. B) PCR gel 
image identifying all the transgene positive founders. Lane 1: pBR322-MSPI digest ladder, Lane 
2: positive control using the transgene plasmid, Lane 3: pCAGGs-PPT1 plasmid, Lane 4-11: 
transgene founder lines. C) PCR gel identifying spontaneous recombination in Founder #42. 
Lane 1: 1Kb ladder, Lane 2: pBR322-MSPI digest ladder, Lane 3: in vitro Cre recombinase and 
transgene plasmid, Lane 4: genomic DNA isolated from F42 brain, Lane 5: genomic DNA 
isolated from F42 Liver, Lane 6: genomic DNA isolated from PPT1-/- brain, Lane 7: genomic 





Figure 19. In vitro characterization of F42. A) RT-PCR of brain, heart, and liver from PPT1-/-, 
F42, and WT mice for the PPT1-LAMP1 mRNA transcript. B) Western blot for PPT1-LAMP1 
expression. Protein expression of PPT1-LAMP1 was conducted on primary dermal fibroblasts. 
The left panel was probed for anti-human PPT1. A strong signal was detected at ~40 kDa in the 
F42 lane, and at the predicted ~32 (unglycosylated) and ~36 kDA (glycosylated) in the human 
control fibroblasts. The right panel was probed for the C-terminus of LAMP-1. There was a 
signal at ~120kDa (endogenous LAMP1) in all lanes and ~40kDA (PPT1-LAMP1) signal in the 
F42 lane. C) Transwell experiment for ‘cross-correction’. Primary dermal fibroblast cells were 
used. There was a significant increase in enzyme activity in the WT-PPT1 compared to PPT1-/- 
cells. F42 cells have ~6-fold greater levels of PPT1 activity compared to WT cells. There was an 
increase in PPT1 activity in the transwell inserts in the WTPPT1 transwell compared to PPT1-/- 
and F42 transwells.  
  
PPT1-LAMP1 expression in vivo is ubiquitous and prevents AFSM 
A survey of tissues for PPT1 activity and secondary enzyme elevations was conducted in 
Founder 42 mice. Supraphysiological levels of PPT1 activity were detected in the brain and 
heart, and lower enzymatic activity in the kidney and spleen compared to wildtype. Surprisingly 
we detected very low PPT1 activity in the liver (Figure 20A). As previously shown, there was a 
secondary elevation in β-glucuronidase activity in the PPT1-/- brain, heart and liver as compared 
to wildtype (Griffey et al, 2004). This secondary elevation was restored to wildtype β-
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glucuronidase activity levels in the brain and heart of F42 animals. However, there was not a 
significant reduction in the secondary elevation of β-glucuronidase activity in the liver compared 
to the PPT1-/- liver (Figure 20B). Autofluorescent storage material was examined in the brains 
and livers of PPT1-/-, WT, and F42 mice. As expected, there was widespread AFSM throughout 
the brain and liver of PPT1-/- animals and none detected in the wildtype animals. Accumulation 
of AFSM was not detected in the cortex, hippocampus, thalamus, or cerebellum of F42 brains. 
However, there was abundant AFSM throughout the liver in hepatocytes and cells of the 
reticuloendothelial system (Figure 20C & 20D). 
Figure 20. Biochemistry and Histology in F42. A) PPT1 enzyme activity tissue survey. 
Supraphysiological levels of PPT1 activity were detected in the brain and heart. Near normal 
levels were detected in the kidney, and ~50% activity in the spleen. The liver had very low 
activity. B) β-glucuronidase activity in the brain, heart, and liver from F42 and controls. There 
was a significant increase in β-glucuronidase activity in the brain and liver of PPT1-/- animals 
compared to WT (p<0.05). β-glucuronidase activity was normalized to WT levels in the F42 
brain, however, the β-glucuronidase activity was not reduced in F42 liver. The heart showed a 
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small increase in β-glucuronidase activity in PPT1-/- animals but this increase was not 
statistically significant. There appeared to be decreased β-glucuronidase activity in the F42 heart. 
C) AFSM accumulation in F42 and control brains. Representative images show AFSM 
accumulation in PPT1-/- brains (cortex and cerebellum). AFSM was not detected in F42 cortex 
or cerebellum. D) AFSM accumulation in F42 and control liver. Representative images show 
AFSM accumulation in PPT1-/- and F42 livers.   
 
PPT1-LAMP1 ubiquitous expression in vivo prevents behavioral decline and 
extends longevity 
PPT1-/- mice showed a significant decline in ERG amplitudes and motor function by 7 
months of age, and are terminal by ~8.5 months. Physiological characterization of F42 showed 
that PPT1-LAMP1 expression prevented the decline in both dark-adapted and light-adapted ERG 
amplitudes (Figure 21A). At 7 months, the motor function of F42 animals, as measured by the 
latency to fall off the rotarod, was identical to wildtype mice (Figure 21B). Lastly, the F42 mice 
are able to live to at least one year without any motor deficits or other obvious clinical signs of 
disease (Figure 21C). 
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Figure 21. Functional and Clinical parameters of F42. A) Electroretinography of F42 and 
control eyes. There was a significant increase in b-wave amplitudes in the light-adapted 
(p<0.001) and dark-adapted (p<0.001) in WT compared to PPT1-/- mice. Similarly, there was a 
significant increase in b-wave amplitudes in light-adapted (p<0.01) and dark-adapted (p<0.001) 
in F42 compared to PPT1-/-. There was no significant difference between F42 and WT B) 
Rotarod of F42 mice showed no deficit in motor function at 7 months of age. C) The lifespan of 
F42 mice (orange) was not reduced compared to WT animals out to one year; PPT1-/- animals 
had a median lifespan of 238 days (blue).  
 
Discussion 
Lysosomal storage diseases are simple monogenic diseases that present with a complex 
clinical phenotype. This is because lysosomal enzymes are ubiquitously expressed and, when 
deficient, affect many cell types. A more thorough understanding of the role individual cell types 
play in the disease process will allow for the rational development of more effective therapies. 
While ‘cross-correction’ has been a boon for therapy, it interferes with our ability to address 
basic biological questions about the role of specific cell types in disease progression. Any 
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attempt to correct the disease in a cell-specific manner would yield inconclusive, confounding 
results. Therefore, in this study, a novel method was employed to prevent cross-correction in an 
attempt to limit PPT1 expression to specific cell types.  
A previous study by Marathe et al, (2000) showed that it was possible to prevent the 
secretion of sphingomyelinase, another soluble lysosomal hydrolase. Sphingomyelinase has been 
shown to be processed differentially depending on whether it will be targeted to the lysosome or 
secreted. In an effort to sequester the secreted form, SMase was tethered to the lysosomal 
membrane using the C-terminus of LAMP-1. The authors created a transgenic/knockout model 
that had modest lysosomal SMase activity in the brain (approximately 20% WT) and lower 
activity in visceral tissues (1-14%). This model had no evidence of neurological disease but 
widespread systemic disease. The original goal of their study was to eliminate the secreted form 
ubiquitously, which resulted in a hybrid model of Neimann-Pick A/B with visceral disease but 
no neurological disease.  
In the current study, the original goal was to achieve cell-specific expression of PPT1. 
However, due to spontaneous rearrangement, a model with ubiquitous expression of tethered 
PPT1 was created. This model (F42) had AFSM in the liver but was otherwise biochemically, 
histologically, and clinically normal. This demonstrates proof-of-principle that PPT1-LAMP1 
can hydrolyze its normal substrates and prevent INCL.  
Tethering of PPT1 to the lysosomal membrane using the transmembrane domain and C-
terminus of the LAMP-1 protein does not alter the enzymatic activity of PPT1. In addition, 
PPT1-LAMP1 was faithfully trafficked to the lysosome where it functions similarly to native 
PPT1. Importantly, PPT1-LAMP1 does not ‘cross-correct’ neighboring cells. In both in vitro 
experiments using either transduced cells or primary fibroblasts from F42, PPT1 activity was 
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expressed six-fold greater than normal and no enzymatic activity was detected in the transwell 
insert.  
Ubiquitous expression of PPT1-LAMP1 in vivo was capable of preventing the 
accumulation of AFSM in the brain. This indicated that restoration of PPT1 by tethering it to the 
lysosomal membrane was sufficient in preventing the accumulation of AFSM. Moreover, the 
expression of PPT1-LAMP1 ubiquitously was able to prevent the onset of the major 
clinical/behavioral signs such as shortened lifespan, reduced visual function, and motor 
dysfunction. Similar to the in vitro experiments, there was also no evidence of PPT1-LAMP1 
secretion or ‘cross-correction’ in vivo. The brain and heart of F42 have PPT1 activity 
approximately 10-fold greater than normal, while kidney and spleen have nearly normal and 
~50% normal levels of activity, respectively. The liver only expresses ~5% normal levels of 
PPT1 activity. On histological examination, the liver of F42 has widespread AFSM 
accumulation. Given the high level of expression in other tissues, if PPT1-LAMP1 were capable 
of ‘cross-correction’, we would predict that the liver would have higher levels of activity and no 
AFSM accumulation. 
In order to accomplish our original goal of generating a mouse model that would have 
cell-specific expression of PPT1LAMP1, a loxP-STOP-loxP system was utilized. However, 
during the initial characterization of the transgenic lines on a PPT1-/- background, enzymatic 
activity was detected in the absence of Cre-recombinase indicating a possible spontaneous 
recombination of the loxP sites. Generation of F42 utilizing the conventional transgenic 
approach led to multiple copies of the transgene (~11 transgene copies/genome). It has been 
shown that this method results in the generation of multiple head-to-tail copies (Haruyama et al, 
2009). It is possible that the repeat sequences in the concatamers make the transgene prone to 
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recombination. Consistent with this hypothesis, it has been shown that direct sequence repeats 
can to lead to deletion of the internal sequence (i.e. loxP-STOP-loxP) (Bill & Nickoloff, 2001; 
Hendricks et al, 2003; Wurtele et al, 2005). Such an occurrence could lead to excision of the 
loxP-STOP-loxP region and allow for transcription of the transgene. The varying levels of 
expression among tissues could be due to the integration site. One potential solution to this 
problem would be to knock-in the transgene into the ROSA26 locus to control for copy number 
and random integration. 
While the transgenic model may not allow for the study of cell autonomy in an in vivo 
setting, the model provides evidence that this basic approach is sound. In addition, the generation 
of a constitutively expressing, near-ubiquitous PPT1LAMP1 will allow for the study of cell-cell 
interactions in an in vitro environment. Lastly, this concept of tethering a soluble lysosomal 
enzyme to the lysosomal membrane may be applied to other LSDs and improve our 





























Summary and Conclusions 
 Infantile neuronal ceroid lipofuscinosis is an inherited metabolic disorder that is caused 
by a deficiency in the soluble lysosomal hydrolase palmitoyl-protein thioesterease-1 (PPT1) 
(Haltia et al, 1973b; Santavuori et al, 1973; Vesa et al, 1995). Deficiency in PPT1 leads to 
lysosomal distention, accumulation of AFSM, and cellular dysfunction. Ultimately, PPT1 
deficiency leads to complex clinical signs. The development of the PPT1-/- mouse model has led 
to a much deeper understanding of disease pathogenesis as well as development of pre-clinical 
treatments (Gupta et al, 2001). Over the past 15 years, the field has benefited from the 
characterization of neuropathology in the PPT1-/- mouse. Studies, to date, have shown that INCL 
disease in the brain is progressive both temporally and spatially (Bible et al, 2004; Kielar et al, 
2007; Macauley et al, 2009). There is astrocytosis, neurodegeneration, and neuroinflammation. 
This histopathology correlates with the clinical signs of disease such as visual deficits, motor 
dysfunction, and reduced lifespan. Due to the cortical atrophy and dramatic decrease in brain 
mass, the NCL field has largely focused on disease within the brain while the disease in the 
spinal cord has been largely overlooked. Similarly, detailed characterization of the peripheral and 
autonomic nervous systems as well as the systemic disease have not been conducted. 
 
A new target and effective therapy for INCL 
 This study identified a novel region of disease and sought to treat it using gene transfer. 
In this study, we transitioned from the second generation AAV2/5 vector to the third generation 
AAV2/9 vector. The AAV2/9 vector has been shown to have improved distribution and 
transduction efficiency compared to previously used gene therapy vectors (Dayton et al, 2012; 
Schuster et al, 2014). Given the AAV2/9 vector’s superior characteristics, we predicted that the 
lifespan of PPT1-/- mice receiving intracranial injections would have been extended longer than 
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the two months observed. This prompted us to perform a more detailed examination of the spinal 
cord in treated and untreated mice in collaboration with Dr. Jonathan Cooper’s lab at King’s 
College, London.  
 A more comprehensive examination of the PPT1-/- mouse spinal cord revealed gross 
anatomical changes as well as more subtle histological changes. It was revealed that there was a 
similar but earlier onset of histopathology in the spinal cord compared to the brain. While the 
volume of white matter increased temporally in the PPT1-/- spinal cord, the volume did not 
approach that of wild-type mice. Interestingly, the grey matter in the PPT1-/- spinal cord 
decreased whereas the wildtype grey matter increased. The hallmark of INCL, autofluorescent 
storage material, was prevalent in the grey matter and progressively increased starting as early as 
two months. Astrocytosis and microgliosis were observed as early as two months of age 
throughout the spinal cord. This was followed by neuronal loss at three months of age. All three 
parameters continued to degenerate in the PPT1-/- spinal cord compared to the wild-type spinal 
cord until PPT1-/- mice are terminal. The finding of widespread spinal cord disease was 
recapitulated in autopsy samples from human INCL patients (Nelvagal et al, In preparation). 
These data suggest that PPT1-/- leads not only to the progression of INCL, but may also 
influence neurodevelopment. 
 In the spinal cords of intracranial-treated mice, the disease was not treated regardless of 
which AAV vector was used. In this study, we showed that there was accumulation of AFSM, 
and an increase in histological markers of disease (CD68 and GFAP) when treatment was limited 
to the brain. This led to the hypothesis that treating the spinal cord directly via gene transfer 
techniques would prevent disease. This also led to the second hypothesis that treating PPT1-/- 
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mice by both intracranial and intrathecal routes would significantly improve the histology, 
improve motor function, and extend the lifespan as compared to either treatment alone.  
 There appears to be a reciprocal response when comparing intracranial to intrathecal 
injections in PPT1-/- mice. When PPT1-/- mice are treated with intracranial AAV2/9-hPPT1, the 
disease in the brain is corrected, however the spinal cord remains diseased. In contrast, when 
PPT1-/- mice are treated with intrathecal AAV2/9-hPPT1, the disease in the spinal cord is 
corrected whereas the brain is still affected. A biochemical surrogate for therapeutic efficacy is 
decreased secondary elevations of other lysosomal enzymes. Secondary elevations of β-
glucuronidase in the brain are significantly reduced in intracranial-injected mice alone and only 
slightly improved in intrathecal-injected mice. The lack of biochemical improvement in the brain 
following intrathecal injection was somewhat surprising given that two to five percent of wild-
type PPT1 activity levels in the brain were detected throughout the study. It has been shown that 
a very small percentage of wildtype lysosomal enzyme activity levels are required to correct the 
disease pathology (Sands et al, 1994). In the regions targeted by gene therapy, there was a 
decrease in histological markers of disease (AFSM, CD68, and GFAP). Particularly in 
intracranial-injected animals, there were improvements in gross physiology (cortical thickness, 
brain weight) which was not observed in the intrathecal-injected mice alone. When cytokine 
levels were examined in the brain, there was a decrease in cytokine/chemokine levels in the brain 
of intracranial treated mice but not in the intrathecal alone. Interestingly, in the intrathecal-
injected mice alone, there was still an upregulation of cytokines/chemokines, which may be due 
to circulating neuroinflammatory factors in the cerebral spinal fluid. When either disease region 
was targeted, there was an improvement in motor function and an extension in lifespan. The 
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histopathology of the treated mice suggest that disease outside of the treated regions could 
explain the reduced motor function and reduced lifespan as compared to wild-type mice. 
When these diseased regions were targeted in combination, there was a significant 
decrease in histological markers of disease in the brain and spinal cord. Furthermore, there was a 
return in neuroinflammatory factors in the brain to wild-type levels. There was also a significant 
improvement in gross brain anatomy. Overall, there was a dramatic and significant improvement 
in motor function and extension in lifespan. The combination intracranial and intrathecal-injected 
mice are by far the longest-lived treated PPT1-/- mice (22 months) reported to date.  
 
Conclusion from combination therapy  
The identification and characterization of the spinal cord disease and the efficacy of 
targeting the spinal cord with AAV-based gene therapy are two overarching findings of these 
studies. First, the disease in the spinal cord begins early in the pathogenesis of INCL. In fact, 
significant disease in the spinal cord begins about one month earlier than disease in the brain. For 
therapeutic purposes, this argues for early treatment of the spinal cord. Moreover, our study also 
shows that persistent expression of PPT1 in the spinal cord is necessary for an extension in the 
quality of life of PPT1-/- mice. A previous study where enzyme replacement was delivered 
intrathecally in PPT1-/- mice showed that lifespan was only extended by one month. Taken 
together, these two aspects suggest that proper identification and treatment for INCL must begin 
early in life (newborn screening) with methods that supply persistent PPT1 to the entire central 
nervous system.  
Second, while INCL disease has primarily been seen as a brain disease, our work 
demonstrates that it is necessary to evaluate the disease in the context of the entire central 
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nervous system. As we have shown, targeting the entirety of the central nervous system 
significantly improves motor function and lifespan of the PPT1-/- mice and slows the 
progression of INCL-related disease. While intracranial and intrathecal administration of 
AAV2/9 showed broad distribution in the central nervous system, the histochemical stain 
determined that the mid-brain was not targeted. Subsequent analysis of this region in treated 
mice showed significant disease that appeared only minimally decreased upon combination 
therapy. Recent studies have employed the intrathecal route as a means to target the brain (Gray 
et al, 2013; Guo et al, 2016; Hordeaux et al, 2015; Schuster et al, 2014). As our study suggests, 
when using single-stranded AAV2/9 (ssAAV2/9) for intrathecal gene therapy, the correction of 
the brain is minimal. Therefore, to target the entirety of the central nervous system, it is 
necessary to utilize multiple routes of injection or to develop vectors that will be better 
distributed within the brain parenchyma (see Future Directions). Since PPT1 is ubiquitously 
expressed, it is also necessary to evaluate the disease outside of the central nervous system such 
as the peripheral and autonomic nervous systems. Given the cardiac dysfunction and metabolic 
abnormalities associated with INCL, it is also necessary to understand whether neuronal 
dysfunction plays a vital role in these aspects of disease (see Future Directions).  
In a more global context, infantile NCL is one of more than 14 different NCLs. While the 
age of onset varies depending on the genetic mutation, the accumulation of AFSM, the increase 
in histopathological markers of disease, the progression of disease within the brain, and the 
overall clinical signs are relatively similar. The findings from our study along with Nelvagal et 
al. moves the field forward by broadening the focus of NCL diseases from the brain to the 
entirety of the central nervous system. It is not difficult to hypothesize that these NCLs would 
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also have progressive spinal cord disease and that treatment for the NCLs will need to include 
treatment of the spinal cord.  
 
Future Directions for INCL gene therapy 
Developmental defect in the spinal cord and peripheral nervous system disease 
 Our data, in combination with Nelvagal et al, suggest that there may be a developmental 
component to INCL particularly in the white matter tracts of the spinal cord. It has been 
previously shown that there is developmental-dependent PPT1 mRNA expression in the rat brain 
in early life (Isosomppi et al, 1999; Suopanki et al, 2000; Zhang et al, 1999). This is not 
surprising given that palmitoylation has been shown to play a key role in neurodevelopment and 
neural function (Fukata & Fukata, 2010; Young et al, 2012). PPT1 has also been shown to be 
localized throughout the axon and at synapses (Ahtiainen et al, 2006; Ahtiainen et al, 2003). 
Furthermore, PPT1 deficiency in mice has shown altered synaptic vesicle recycling (Kim et al, 
2008; Virmani et al, 2005). In Drosophila, PPT1 has been shown to regulate neural cell fate and 
specification. In PPT1-/- larvae, there are a variety of defects in axonal guidance and branching 
(Chu-LaGraff et al, 2010; Glaser et al, 2003). This suggests that PPT1 deficiency may alter 
neuro-development.  
While many studies have been conducted on the progression of INCL in mice after two to 
three months, it is necessary to study the developmental defects of PPT1 deficiency either at 
embryonic or early post-natal stages. It has been shown in Drosophila that the defects in axonal 
guidance and targeting affect the entire nervous system. The visualization of axonal guidance 
and targeting can be addressed with the development of the Thy1-YFP PPT1-/- reporter mouse 
model. The Thy1-YFP reporter mouse labels some neurons of the motor and sensory cortex, the 
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corticospinal tract, and the sciatic nerve. Furthermore, this reporter model has been used to 
examine neuromuscular junctions. With the Thy1-YFP PPT1-/- reporter mouse model we will be 
able to follow axonal guidance and targeting defects from the brain to the signaling endpoint. By 
comparing the PPT1-/- mice to the wild-type littermate, we may begin to unravel how PPT1 
deficiency contributes to the functional deficits at the cellular level.  
 
Synergy of spinal cord and brain directed therapy 
 It is necessary to understand the role of the entire central nervous system in disease 
progression. As shown, while targeting the brain or the spinal cord individually led to modest 
increases in lifespan and function, targeting both regions simultaneously significantly improved 
histological and clinical parameters compared to either region alone. In fact, targeting both 
regions of the CNS leads to an apparent synergistic effect. If the two routes of administration 
resulted in an additive effect, the median lifespan would have been approximately 17 months. 
However, the lifespan of mice treated with both intrathecal and intracranial injections was 19.3 
months. A similar synergistic effect was observed with motor function. An additive effect would 
have resulted in motor deficits presenting at 11 months. However, significant motor deficits were 
not observed until 15 months. A more thorough understanding of this synergy could guide the 
future development of more effective therapies. 
AAV2/9 has been shown to target a variety of cell types, particularly during the early 
post-natal periods (Foust et al, 2009). To understand the synergy, it may be necessary to limit the 
expression of PPT1 to select cell types such as neurons or glia using cell-specific promoters in 
the AAV cassette instead of the ubiquitous CAG promoter. However, utilization of AAV may 
not correct the entirety of each cell type leading to potential confounding results. To ensure 
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broad expression of PPT1, it may be more beneficial to develop a mouse model where there 
could be cell-specific expression of PPT1. We have made significant strides in the development 
of this model (see Chapter 3: Cell-specific Expression of PPT1).  
The synergy that we observed may be due to both a better distribution of PPT1 
throughout the central nervous system as well as to the peripheral nervous system. It has been 
shown that intrathecal injection of an AAV vector can result in significant expression in the 
peripheral nervous system (Federici et al, 2012; Jacques et al, 2012; Vulchanova et al, 2010). 
The peripheral and autonomic nervous systems in PPT1 deficient animals have not been 
characterized. It will be important to examine the impact of CNS-directed gene therapy on the 
peripheral nervous system. Performing gene therapy experiments in the Thy1-YFP PPT1-/- 
reporter mouse model might provide insights into the consequences of this approach on the 
peripheral nervous system. Finally a thorough biochemical, histological, and functional 
assessment of the systemic disease in AAV-treated mice might be informative..  
 
Improved Combination Therapies 
Combination therapy in lysosomal storage diseases has shown tremendous promise 
(Hawkins-Salsbury et al, 2011). By expanding the region targeted by CNS-directed gene therapy, 
we were able to more than double the lifespan of PPT1-/- mice. By targeting regions of the 
central nervous system not previously corrected, we were able to significantly delay disease 
onset. However, the lifespan of the combination treated animals were still shorter than the wild-
type littermates. There is still much more to be accomplished in order to completely correct the 
disease. In order to treat INCL and other storage disorders effectively, it will be necessary to 
correct the entirety of the system or organ and not simply a small portion. While ‘cross-
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correction’ is a relatively efficacious method to deliver enzyme, it’s radius of correction is 
limited. 
The use of AAV viral vectors to target the CNS in INCL has been beneficial due to the 
distribution of the AAV vector within the parenchyma. With improving CNS-specific vector 
serotypes, the distribution of the vectors will only improve. As we showed with the histological 
stain for PPT1, the PPT1 staining is broad and diffuse throughout the CNS. However, one region 
that has marginal staining is the thalamus and mid-brain region. The thalamic region has been 
shown to be the first area affected in INCL with both neuronal loss and glial activation. The 
thalamic region appeared to have only minimally decreased histological markers of disease in the 
combination-treated animals and there was no decrease in the animals receiving individual 
treatments. This suggests yet another therapeutic target using AAV2/9 gene therapy. Another 
method to target the thalamus would be to employ another AAV vector serotype (e.g. AAV-DJ) 
or a self-complementary AAV that has a broader distribution and increased transduction 
efficiency (Fu et al, 2003; Mao et al, 2016).. In either case, this could lead to an increase in the 
level of enzyme produced and broader correction. 
Small molecule drugs have been explored to replace PPT1 activity (PPT1 mimetics) or 
target secondary effects of PPT1 deficiency (neuroinflammation). Unfortunately, these small 
molecule therapies have resulted in little to no improvement in functional parameters of INCL 
such as motor function or longevity. For example, using the anti-inflammatory Minozac, there 
were minor improvements in histological markers of disease in the brain but functional tests 
remained unchanged (Macauley et al, 2014). Similarly, using a PPT1 mimetic, 
phosphocysteamine, there was no biochemical, histological, or functional improvements in INCL 
mice (Roberts et al, 2012). Although these small molecule drugs provide little or no benefit on 
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their own, they might interact with another form for therapy (e.g. gene therapy) to greatly 
increase efficacy.  
INCL is considered primarily a neurological disease. However, systemic disease is 
present in mice and could be relevant for humans (Galvin et al, 2008; Woloszynek et al, 2007). If 
treatment is limited to the CNS, then the systemic disease could become clinically relevant. To 
tackle systemic disease, enzyme replacement studies have shown that intravenous delivery of 
recombinant PPT1 corrects INCL histopathology in the visceral tissues however this does not 
significantly improve outcome measures such as lifespan or motor function (Hu et al, 2012). 
Therefore, to treat INCL disease in its entirety, it may be necessary to combine CNS-directed 
gene therapy with recombinant enzyme replacement therapy.  
Another combination therapy that may be useful is gene therapy in combination with 
substrate reduction. Substrate reduction therapy (SRT) is accomplished by inhibiting the 
synthesis of the substrates for the enzyme that is deficient. Although in principle SRT is not 
predicted to stop the disease, it could slow the accumulation of undegraded substrates and 
potentially slow disease progression. SRT is currently in clinical trials for several LSDs (Cox, 
2005; Pastores, 2010; Valayannopoulos, 2013). Therefore, SRT might be an ideal adjunct 
therapy for INCL. In fact, dramatic results have been achieved in the mouse model of Krabbe 
disease by combining SRT with CNS-directed gene therapy (Hawkins-Salsbury et al, 2015). SRT 
could be utilized in INCL by targeting the palmitoylation of proteins. Within the cell, the 
dynamics of palmitoylation is in equilibrium and has been shown to involve DHHC proteins and 
acyl-protein thioesterases (Fukata et al, 2015; Fukata et al, 2013; Fukata & Fukata, 2010; Fukata 
et al, 2016; Martin et al, 2012). Ultimately, palmitoylated proteins are degraded in the lysosome. 
Therefore, to reduce the influx of palmitoylated proteins into the lysosome, one method could be 
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a reduction in the cellular pool of free palmitate. Palmitate is produced in the cell by the 
multimeric enzyme fatty acid synthase (Smith et al, 2003). Inhibition of palmitate synthesis can 
be accomplished by using small molecule drugs that competitively inhibit fatty acid synthase 
(Abdel-Magid, 2015). There are a number of FASN inhibitors such as the C75 (a cerulenin 
derivative), orlistat, and epigallocatechin-3-gallate (EGCG, green tea derived). When combined 
with CNS-directed gene therapy, it could be possible to attenuate the severity of the disease. 
 
Summary of cell-limited study of PPT1 
 Given the complex nature of INCL, this study sought to develop a model where INCL 
could be studied in a cell-specific manner. The cell-specific study of INCL is hindered by ‘cross-
correction’. For example, correction of neurons with soluble PPT1 would ultimately correct the 
neighboring glia making the interpretation of the results inconclusive. To prevent cross-
correction, we tethered PPT1 to the lumen of the lysosome. This was done by genetically 
engineering the human PPT1 cDNA to the C-terminus and transmembrane domain of the 
lysosomal-associated membrane protein-1 (LAMP1).  
 In this study, PPT1 was tethered to the C-terminus of LAMP-1 using a six-glycine linker. 
We showed that the PPT1-LAMP1 chimeric protein retained enzymatic function and was 
incapable of ‘cross-correction’ in vitro. We developed lentiviral constructs that expressed either 
wild-type human PPT1 or the chimeric PPT1-LAMP1 and transduced PPT1-deficient cells. We 
showed that PPT1-LAMP1 had similar enzymatic activity as the wild-type PPT1. Using a 
transwell setting, we further show that PPT1-LAMP1 was incapable of ‘cross-correcting’ 
deficient cells in the transwell insert.  
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 Since our overarching goal was to express PPT1 in a cell-specific manner, we sought to 
limit PPT1-LAMP1 expression to particular cell types. Therefore, we employed current 
transgenic technology using the Cre-loxP system. We genetically inserted PPT1-LAMP1 into a 
transgene driven by the ubiquitous CAG promoter. For cell-specificity, we inserted a LoxP-
STOP-LoxP sequence within the transgene. This system functions properly in vitro. Therefore, 
we proceeded to create animals harboring this Cre-responsive transgene. A preliminary 
examination of Founder #42 (F42) revealed PPT1 activity throughout the mouse with 
supraphysiological levels detected in the brain and heart, and low levels in the liver. This global 
activity in the absence of Cre recombinase would not allow for cell-specific expression in vivo. 
 Ultimately, we decided to characterize F42 as a proof-of-concept model. We showed that 
PPT1-LAMP1 is expressed in vivo and that it is localized to the lysosome. Using a transwell 
system, we showed that PPT1-LAMP1 is not secreted from primary dermal fibroblasts derived 
from F42. This is further confirmed in vivo upon examination of the liver. While there were low 
levels of enzymatic activity in the liver, we observed the hallmark of INCL disease, AFSM, in 
sporadic cells throughout the liver such as in the hepatocytes and Kupffer cells. This indicated to 
us that PPT1 is not being secreted and taken up by neighboring cells. Expression of PPT1-
LAMP1 corrected all of the INCL clinical signs measured such as visual deficits as measured by 
ERGs, motor function via rotarod, and lifespan. This shows that expression of PPT1-LAMP1 can 
complement native soluble PPT1.  
 
Conclusions from cell-specific expression of PPT1 
 We have generated a model that has cell-limited but ubiquitous expression of PPT1. This 
was most likely due to a spontaneous recombination of the loxP-STOP-loxP within the transgene 
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as was detected by PCR analysis of the genome. While this model cannot be used for the 
intended purpose, the model instead can be used to study in vitro effects of sequestered PPT1. 
Cell-specific studies can still be conducted in a mixed culture setting (discussed further in Future 
Directions). We have shown that it is possible to sequester a soluble lysosomal hydrolase within 
the lysosome and that this sequestration does not impede the ability of the enzyme to function. 
Therefore, with some modifications, it may be possible to express PPT1-LAMP1 in a cell-
specific manner and begin to understand the role of different cell types in INCL. On a grander 
scale, this conceptual approach can be applied to a variety of lysosomal storage disorders that 
result from deficiencies in a soluble lysosomal hydrolase (e.g. Krabbe disease, MPS disorders). 
These LSDs suffer from the same confounding nature of ‘cross-correction’. By better 
understanding the pathogenesis of these LSDs and the major cell types that are affected, we may 
begin to develop more targeted therapies. 
 
Future Directions for Cell-specific Study of INCL 
Modification of the Transgene 
‘Cross-correction’ remains a hindrance to the study of specific cell types in lysosomal 
storage diseases. The generation of the PPT1-LAMP1 chimeric enzyme prevents ‘cross-
correction’ as we have shown. While the F42 model for PPT1-LAMP1 expression may be useful 
for in vitro studies, for cell autonomous studies of INCL in vivo, the model is still lacking. The 
original concept of utilizing the Cre-loxP system for cell-specific expression of PPT1-LAMP1 
could still prove to be the most useful. One scenario that may have contributed to spontaneous 
recombination of the loxP sites in F42 is the methodology in the generation of the transgenic 
mice. We utilized a conventional transgenic approach where our transgene was micro-injected 
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into mouse embryos. This method is prone to concatamer formation at a variety of integration 
sites. The concatamers in turn might be prone to recombination particularly with large regions of 
repeat sequences. To prevent this, we could take advantage of the ROSA locus. The ROSA26 
locus has been shown to be targeted with high efficiency and can be limited to a single copy of 
the transgene (Beard et al, 2006; Zambrowicz et al, 1997).  
It has additionally been shown that a strong promoter can read-through a loxP-STOP-
loxP sequence. While infrequent, this could also lead to confounding results. One scenario to 
overcome this problem would be to utilize the double-floxed inverted orientation (Smedemark-
Margulies & Trapani, 2013; Sohal et al, 2009). This system utilizes two sets of incompatible 
loxP sites that flank the inverted transgene, and, when subjected to Cre-recombinase, result in an 
inversion of the transgene to its functional form. This method would not require the presence of a 
STOP sequence in the transgene and any spontaneous recombination would not result in a 
functional transgene.  
Finally, we could re-engineer our transgene to contain loxP sites outside of the expression 
cassette. In this strategy, we would have ubiquitous expression in the absence of Cre 
recombinase but could ‘turn-off’ the expression in a cell-specific manner.  
 
Mixed culture studies  
While the current model cannot be used for in vivo examination of specific cell types in 
INCL, in vitro studies can be conducted using mixed cultures. We have developed lentiviral 
vectors that express either hPPT1-LAMP1 or wild-type hPPT1, and an empty vector control. The 
PGK promoter, a ubiquitous promoter, drives the transgenes in these lentiviral vectors. 
Moreover, there is a selectable puromycin marker. It will be possible to transduce specific cell 
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types (e.g. neurons, astrocytes) from PPT1-/- animals and by co-culturing these cells with other 
cell types, begin to understand how PPT1 deficiency affects intra- and inter-cellular interactions. 
For example, we may begin to understand the PPT1-/- neuronal phenotype by co-culturing 
PPT1-/- neurons with lentiviral-transduced PPT1-/- astrocytes in vitro. Similar studies can be 
conducted using isolated primary cell cultures from the F42 transgenic line.  
To mimic in vivo settings, we could change the promoter of these lentiviral vectors from 
a ubiquitous promoter to cell-specific promoters. We could inject these lentiviral vectors into 
newborn mouse brains. While this will not allow for the targeting of every cell for a specific cell 
type, it will allow for the study of a specific cell type in a defined region. For example, the 
lentiviral vectors could be injected in the thalamus of PPT1-/- animals, one of the first sites of 
CNS disease, and these animals could be later observed for changes in biochemistry, histology, 
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